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ABSTRACT 
AIMS                                                                                                                                                
To determine the cardio-metabolic risk profile and incidence of low bone mineral density in 
African and Indian postmenopausal women attending the IALCH menopause clinic and to 
determine whether there is a correlation between cardio-metabolic parameters and low bone 
mineral density. 
 
METHODS                                                                                                              
A retrospective, descriptive study involving all Indian and African postmenopausal women, 
above the age of 40, referred to the menopause outpatient clinic at IALCH from 01 July 2009 
to 31 December 2010 was conducted.  
Data was collected from the medi-com database using a structured questionnaire.  
Cardio-metabolic data was analysed as continuous variables and summarized using means 
and standard deviations. Bone mineral density was treated as a quantitative variable and 
correlation analysis was used to assess relationships between the variables. This was done for 
each race group separately. The Students T-test was used to compare cardio-metabolic 




The records of 106 women were analysed (51 African and 55 Indian). In African and Indian 
women, the prevalence of hypertension was 54.9% vs 65.5%, the prevalence of diabetes was 
31.4% vs 56.4%, the prevalence of dyslipidaemia was 17.6% vs 32.7% and the prevalence of 
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ischaemic heart disease was 5.9% vs 14.9% respectively. The prevalence of low bone mineral 
density was higher in Indian women (40%) compared to African women (23.5%). The mean 
body mass index (BMI) of African women was significantly higher than Indian women, (33 
vs 29). There were no significant differences between African and Indian postmenopausal 
women regarding their lipid profile, fasting glucose, fasting insulin and thyroid profile.  
 
The mean bone mineral density (BMD) in the hip and spine was lower in Indian women 
compared to African women, however the prevalence of osteopaenia and osteoporosis, as 
defined by T-scores, was not statistically significant.  
 
Statistically significant positive correlations were observed between an increasing BMI and 
BMD (p<0.001) and increases in weight and BMD (p<0.001). A statistically significant 
correlation were observed between serum LDL-cholesterol values and BMD (p=0.03), where 
serum LDL-cholesterol values were inversely proportional to BMD. There were no 
significant correlations between BMD and the remaining cardio-metabolic variables (ie blood 
pressure; waist-hip ratio; clinical stigma of dyslipidaemia; clinical stigma of insulin 




There is a high prevalence of cardiovascular risks and low BMD amongst the local 
menopausal population, irrespective of ethnicity. African and Indian postmenopausal women 
had a high prevalence of hypertension (60%), diabetes (44%), dyslipidaemia (25%) and 
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obesity (54%). In African women, the incidence of low BMD was 35% in the hip, 53% in the 
neck of femur and 55% in the lumbar spine. In Indian women, the incidence of low BMD 
was 55% in the hip, 67% in the neck of femur and 69% in the lumbar spine. BMI and weight 
showed a positive correlation with bone mineral density. Regarding the cardio-metabolic 
variables, an increasing LDL value was negatively correlated with bone mineral density. It 
thus is apparent that a screening lipid profile during the peri-menopausal years, coupled with 
early and appropriate lifestyle management regarding body mass index/ weight may limit the 

























The term menopause is derived from the Greek words ‘men’ (month) and ‘pausis’ (cessation) 
and is defined by the World Health Organisation (1998) as “A permanent cessation of 
menstruation resulting from the loss of ovarian follicular activity marking  the end of a 
women’s reproductive capacity”.  The diagnosis of this hypo-oestrogenic state is made after 
12 months of amenorrhea. 
 
The mean age of menopause is approximately 50 years and 9 months (Rymer et al., 2000), 
with many women living longer than previously recorded. 
 
In 2007, North American hospital statistics revealed that cardiovascular disease was the 
leading cause of death in postmenopausal women. (American Heart Association, Women and 
cardiovascular disease facts, American Heart Association, 2007). Cardiovascular risk 
increases in the menopause, regardless of the age of onset of menopause, and is the leading 
cause of mortality amongst these women (Sturdee et al., 2009). 
 
The increased cardiovascular morbidity and mortality during the menopause may be 
attributed to the changing hormonal status of the menopause which renders women prone to 
the metabolic syndrome. In addition, women are unique as they are not only susceptible to 
the usual risk factors for CVD, but specific risk factors, like a history of polycystic ovarian 
syndrome and pre-eclampsia which, when present, doubles the background risk of a cardiac 
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event (Sturdee et al., 2009). Furthermore, common conditions amongst menopausal women 
such as hypertension, dyslipidaemia, diabetes mellitus, obesity and smoking are powerful 
indicators of cardiovascular events.   
 
Osteoporosis is one of the most detrimental conditions in the elderly, affecting one third of 
postmenopausal women (De Villiers., 2009). Oestrogen deficiency is associated with bone 
loss in postmenopausal women
 
(Bansal and McGregor.,1992), a view reinforced in earlier 
studies by Ohta et al (1992) which demonstrated bone loss after oophorectomy and Ahlborg 
et al (2001) which showed a decrease in the rate of bone loss after oestrogen replacement. 
 
Studies by Finkelstein et al. (2008), Zhao et al. (2007) and Kadam et al. (2010) seem to 
favour the assumption that ethnicity and body weight determine baseline bone density and 
affects the rate of bone mineral loss and fracture. These disparities may be reflected by a 




Finkelstein et al (2008) performed a longitudinal cohort study of African-American, 
Caucasian and Asian women participating in The Study of Women’s Health Across the 
Nation. This study was performed in seven sites across North America. The study reported 
that the average African female was found to weigh 9kg more than the average Caucasian, 
and up to 25-27kg more than the average Asian. In the pre-menopausal or early peri-
menopausal women, lumbar spine BMD loss was accelerated in those with a low body 
weight.
  
Consequently, Asian and Caucasian women demonstrated a higher incidence and 
prevalence of decreased bone mineral density and fracture risk. 
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In addition, Zhao et al (2007) evaluated the relationship between obesity and osteoporosis in 
more than 3000 Caucasian and Chinese postmenopausal women. The study demonstrated that 
bone mass was proportional to fat mass in both Asian and Caucasian women. 
 
In a recent study by Kadam et al (2010), risk factors for low BMD were evaluated in 92 
Indian postmenopausal women. The study demonstrated that both weight and BMI was 
proportional to BMD. 
 
 
Traditionally, cardiovascular disease and osteoporosis were considered distinct and unrelated. 
However, studies by Ness et al (2006), Marcovitz et al (2005), Varma et al (2008) and 
Makovey et al (2008) suggests a pathological link between calcium metabolism, the vascular 
system and blood coagulation, especially in the light of shared, but independent risk factors 
such as dyslipidaemia, altered glucose metabolism and hypertension.  
 
 
Ness et al (2006) performed a retrospective study on 1000 postmenopausal women. Women 
included in the study shared a similar risk profile for atherosclerosis. Women with 
osteoporosis or osteopaenia demonstrated a two-fold higher prevalence of atherosclerotic 
vascular disease than women with normal bone mineral densities. 
Osteoporosis has been suggested as an indicator of cardiac disease in the postmenopausal 
population and a low bone mineral density appears to predict significant CAD in females. 
Marcovitz et al (2005) was the first study to report osteoporosis as an independant predictor 
of CAD in the postmenopausal population, with a five-fold higher risk of angiogram-
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documented CAD in the presence of confirmed osteoporosis.  Varma et al (2008) further 
demonstrated that the prevalence of obstructive CAD (diagnosed on angiogram following 
chest pain) was greater in women with osteoporosis (74%) and osteopaenia (66%) versus 
normal bone mineral density (45%). 
 
To date, the many studies that have addressed this association were unable to determine 
whether this is as the result of an effect-effect relationship, an effect-causal relationship, 
chance or bias. 
 
 
A survey of the literature demonstrates a lack of consensus regarding the relationship 
between bone mineral density and lipid profile (Makovey et al., 2008, D’Amelio et al., 2008 
and Bagger et al., 2007).  
 
 
The relationship between total serum cholesterol and BMD was analysed in a study by 
Makovey et al (2008) where 273 postmenopausal women were assessed. The study found an 
inverse relationship between triglyceride and LDL levels with lumbar spine and whole body 
BMD.  In a smaller descriptive study by D’Amelio et al (2008), serum HDL levels were 
measured in 37 postmenopausal women with osteoporosis. These values were compared to 
43 postmenopausal women with a normal BMD. HDL levels were inversely proportional to 
BMD. Although this data proves interesting, the sample size may impact on the reliability of 
such findings. 
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Conversely, in a prospective epidemiological study of 2662 healthy postmenopausal women, 
Bagger et al (2006) measured BMD, fractures and aortic calcification on an annual basis. The 
study demonstrated that aortic calcification was an independent risk factor for the 
development of osteoporosis. 
 
 
While studies, like those of Makovey et al (2008), shows that a pro-atherogenic profile is 
associated with a favourable BMD,
 
Bagger et al (2006) demonstrated that the rate of bone 




The link between BMD and other cardio-metabolic parameters have also been highlighted in 
literature (Tsuda et al., 2001, Browner et al., 1993, Jorgensen et al., 2001, Uzzan et al., 2007, 
Bruce and Rymer., 2009).      
 
                                                                                                                        




low bone mineral density 
in postmenopausal women was associated with a higher incidence of strokes. For every 
standard deviation decrease in BMD in the calcaneus there was a 1.3 fold increase in 
cerebrovascular risk.  The study concluded that low BMD is a possible predictor of the first 
onset of stroke in female postmenopausal women, independent of age.  
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Tsuda et al (2001) investigated the association between essential hypertension and low BMD. 
He performed DEXA scans and measured urinary calcium levels and blood pressure in 
elderly Japanese women. The study demonstrated that BMD was inversely correlated with 





In a small study by Jorgensen et al (2001), the BMD of approximately 250 Nordic patients 
were measured. 33 women were previously diagnosed with stroke. The study demonstrated 
that the BMD measured at the femoral neck was 8% lower in women who had previously had 
a stroke. Furthermore, women in the lowest quartile for BMD showed a four-fold greater risk 
per standard deviation decrease in BMD for stroke than those in the highest quartile.  
 
 
A meta-analysis of 16 studies (including 3 randomized controlled trials)  by Uzzan et al 
(2007) explored a link between statins and hip BMD. The BMD of the hip in 2971 
postmenopausal women on statins were evaluated The study concluded that statins not only 
played a beneficial role in decreasing atherogenesis, but were associated with decelerated 
bone loss.  
 
While studies show a disparity in the prevalence of low bone mineral density in a multiethnic 
cohort, there are no studies in the literature that compare Indian and African postmenopausal 
women with regard to their cardiovascular risk profile and its relationship to BMD. This 
study attempts to identify and compare the cardio-metabolic risk profile and the prevalence of 
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low bone mineral density in Indian and African postmenopausal women and thereafter, 
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CHAPTER 1 
1.2 THE CARDIOMETABOLIC PROFILE OF MENOPAUSE 
 
Cardiovascular disease (CVD) is associated with significant morbidity and mortality in the 
elderly, independent of age.  
 
Before menopause, women have a favourable cardiovascular profile. This results in a 20 year 
delay, compared to their age-matched male counterparts, in the presentation of cardiovascular 
morbidity like myocardial infarction and sudden death (International Menopause Society 
Consensus statement, Sturdee et al.,2009). This advantage is lost in the menopause. 
Furthermore, women are susceptible to pre-eclampsia or polycystic ovarian syndrome, which 
doubles the background risk for a coronary event. 
 
In women of a reproductive age, oestrogen has a multimodal function as a cardio-protective 
hormone, with both immediate and long term benefits on the cardiovascular system 
(Mendelsohn et al., 1999, Mendelsohn et al., 2002).                  
 
Studies by Mendelsohn et al (2002) demonstrated that the effects of oestrogen are mediated 
by the estrogen receptors ER-α and ER-β. The direct effects of estrogen occur through rapid 
non-genomic and longer-term genomic pathways. Oestrogen is responsible for a favourable 
lipid profile by increasing HDL-cholesterol and lowering LDL-cholesterol. These effects lead 
to a decrease in the total serum cholesterol concentrations, LDL concentrations, lipoprotein A 
(LP-a) concentrations and an increase in HDL.
 
Blood HDL cholesterol levels are consistently 
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higher and total cholesterol and LDL levels are lower in women than men. A decrease in 
HDL-cholesterol of 0.55 mmol/L is associated with a 40 – 50% increased CAD risk (Speroff 
et al., 2005). 
 
After menopause, the risk of CAD doubles for women as the atherogenic lipids, at age 60 
years, reaches levels greater than those of men (Epstein et al., 1991). The Munster heart study
 
by Eriksson et al (1999)
 
documented a strong association between total cholesterol and CAD 
in women, where CAD was three times more prevalent in women with high cholesterol 
values. Epstein et al (1991) demonstrated that the strongest predictor of CAD in women 
remains a low HDL-cholesterol. These findings by Epstein et al (1991) have not been further 
explored in the literature to date. Excess caloric intake and obesity decreases HDL-
cholesterol and increases total cholesterol, LDL-cholesterol and TG levels.  
 
The response of oestrogen to vascular injury and atherosclerosis remains one of the most 
important functions of the hormone (Morales et al., 1995, Mendelsohn et al., 1999). Morales 
et al (1995) suggests that the direct action of oestrogen on blood vessel walls contribute 
substantially to the cardio-protective and direct myocardial effects, with respect to structure 
and function. Oestrogen accelerates endothelial cell growth, both in-vivo and in-vitro after 
denudation. The vascular endothelium is also protected from the toxic effects of LDL as 
oestrogen inhibits LDL oxidation. Additionally, oestrogen promotes vasodilation by down-
regulating the expression on angiotensin 2, the Renin-angiotensinogen system (RAS) and 
endothelin 1, with a resultant increase in endothelial derived NO, promoting relaxation of 
vascular smooth muscle (Morales et al., 1995; Rajzbaum et al., 2006). Oestrogen has further 
effects on the coagulation and fibrinolytic systems with hepatic gene regulation of 
- 13 - 
 
Antithrombin 3, Protein S and fibrinogen concentrations, resulting in an overall increase in 
fibrinolysis (Eriksson et al., 1999). 
 
                                                                                                                  
The aging process is “characterized by progressive endothelial dysfunction and coronary 
artery remodeling” resulting in a decrease in large vessel compliance (Mendelsohn et al., 
2002). This is coupled with an increase in sympathetic activity resulting in an increased blood 
pressure during the menopause transition (Sturdee et al., 2009). The effect of hypertension in 
women, especially in the menopause, is both under-estimated and under-treated. Blood 
pressure increases with age. However, the cut-off for cardiovascular risk is unknown. In a 
clinical context, this translates to individuals with blood pressures deemed ‘normal’ or ‘high-
normal’ being included in primary prevention programmes. 
 
 
Increases in body weight and abnormal fat distribution in the menopause put the older women 
at risk for the metabolic syndrome. This change in body habitus results in peripheral 
resistance to insulin, blood pressure alterations and an atherogenic lipid profile (Carr., 2003). 
In North America, the overall estimated prevalence of the metabolic syndrome is 24%, higher 
in women (with a prevalence of 40% by age 60 years) and increases with age (Bansal et al., 
1992).
  
The prevalence of metabolic syndrome in South Africa is estimated to be 33.5% 
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The International Diabetes Federation (IDF) proposed a definition for metabolic syndrome in 
2005. This is tabulated below. 
 
TABLE 1: DIAGNOSIS OF METABOLIC SYNDROME 
 
FACTOR DEFINITION 
Central obesity + BMI >30kg/m
2 
or waist circumference  ≥88cm 
Hypertension Systolic blood pressure (SBP) ≥ 130mmHg or 
Diastolic blood pressure (DBP)≥ 85mmHg or 
Specific treatment of previously diagnosed 
hypertension 
Reduced HDL-cholesterol <1.29mmol/L or specific treatment for this 
abnormality 
Raised triglycerides ≥1.7mmol/L or specific treatment for this 
abnormality 
Raised fasting plasma glucose ≥6.1mmol/L or previously diagnosed type 2 
diabetes mellitus 
International Diabetes Federation 
 
 
Weight reduction is associated with improved insulin sensitivity, favourable lipid profiles and 
improved blood pressure profiles. Regular physical exercise has been documented to reduce 
cardiovascular risk by 75% (Mosca et al., 2007).  A healthy diet during the menopausal years 
should include fruit, vegetables, protein and fibre. There should be judicious salt intake (<1 
teaspoon per day) and cholesterol intake should be limited to <300mg daily. Calcium (1 gram 
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daily) and Vitamin D (800IU daily) are recommended. There is no consensus on any other 
food supplement (International Menopause Society Consensus statement, 2009).
   
All 
individuals with features of the metabolic syndrome should be aggressively encouraged to 
optimize their diet and lifestyle and achieve appropriate blood pressure levels so as to 
minimize CVD.   
 
 
In view of the multifactorial nature of cardiovascular disease, the European Society of 
Cardiology, the European Atherosclerosis Society and the European Society of Hypertension 
formulated the Systematic coronary risk evaluation (SCORE) chart in 2003 (Appendix D).
 
Unlike the Framingham study, the SCORE chart is based on data from prospective studies 
and mortality statistics of individual countries. The SCORE chart allows the clinician to tailor 




Management is targeted towards a reduction in the incidence of first or recurrent clinical 
events due to coronary heart disease, ischaemic stroke and peripheral artery disease in an 
attempt to minimise morbidity and mortality. To this end, the current guidelines address the 
role of lifestyle changes, the management of major cardiovascular risk factors and the use of 
different prophylactic drug therapies in the prevention of clinical CVD. 
 
 
SCORE has proven to be a quick and effective tool for a cardiovascular death over a 10 year 
period in asymptomatic high and low risk women (Conroy., 2003). The SCORE chart 
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integrates risk factors like gender, age, smoking, systolic blood pressure and either total 
cholesterol or the cholesterol/HDL ratio. Low risk women (<5% risk) are offered advice on 
how to maintain their low risk status, which include lifestyle interventions, body weight 
control, blood pressure monitoring, lipid and glucose control. High risk women ( ≥ 5% risk) 
or women who will reach this level in middle age, should be given maximum attention by a 




With waning ovarian function and the cessation of oestrogen production that hallmarks the 
menopause, cardio-protection is lost. Thus, the true burden of cardiovascular disease on age 
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CHAPTER 1 
1.3 BONE HEALTH IN THE MENOPAUSE 
 
The internationally agreed description of osteoporosis is: “A systemic skeletal disease 
characterized by low bone mass and micro-architectural deterioration of bone tissue with a 
consequent increase in bone fragility and susceptibility to fracture”. 
 
 
The North American National Osteoporotic foundation has shown that osteoporosis affects 
20 million people and results in to 1.5 million fractures per year.
  
Locally, in the era of human 
immunodeficiency virus (HIV) a meta-analysis by Brown et al (2006)
 
found low bone density 
in 67% of HIV positive women, with 15% having osteoporosis.  This statistic translates to a 
more than three times greater prevalence of osteoporosis in HIV-positive women, with this 
being even greater in antiretroviral exposed individuals (Miller et al., 2005). The relationship 
between HIV and low bone mineral density has been investigated in both in-vitro and in-vivo 
studies. HIV was shown to have direct effects on osteoclastic activity with resultant bone 
demineralisation. HIV –induced chronic inflammation, resulting in chronic immune 
activation, was also associated with increased bone resorption. Additionally, antiretroviral 
therapy, namely Protease inhibitors and Nucleoside analogues showed heterogenous effects 
on the bone which included bone demineralisation from increased osteoclastic activity and 
impaired osteoblastic activity.  
 
 
Both osteopaenia and osteoporosis are largely preventable sequele of the menopause. Bone 
health is, however, often an after-thought. Furthermore, although osteoporosis can be 
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effectively managed, it continues to be undertreated, in part because of inadequacies in 
screening and diagnostic procedures.  In view of the morbid consequences of osteoporosis, 
fracture prevention is a paramount consideration. 
 
                                                                          
Bone turnover increases during peri-menopause (Perrien et al., 2006). Bone mineral density 
(BMD) begins to decline substantially during the late peri-menopause, to early post-
menopause (Speroff et al., 2005). Oestrogen deficiency has been identified as a major risk 
factor for osteoporosis in postmenopausal women.  
 
The annual rates of loss during the late peri-menopause or early postmenopausal years are 
approximately 2% in the spine and 1% in the hip (Speroff et al., 2005). Over 5 years, the 
average woman’s BMD would decline 7–10% in the spine and 5–7% in the hip. Bone loss in 
the menopause is associated with approximately 50–100% higher rate of fractures 
(Finkelstein et al., 2008).
  
 
In accordance with the latest guidelines from the Institute of Medicine, postmenopausal 
women require a daily dietary intake of 1200mg elemental calcium. The dosage of 
supplemental calcium should be restricted to cover the shortfall between dietary intake and 
the dietary reference intake – approximately 500mg elemental calcium. Tang et al (2007) 
found that
 
calcium supplementation, in women above 50 years old, resulted in a 12% 
reduction in all types of fractures, with a 24% reduction achieved if compliance on calcium 
was at least 80%. 
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A number of risk factures for low bone mineral density and fractures have been investigated 
in the past.  Examples include age, sex, the degree of bone turnover, a history of osteoporotic 
fractures, lifestyle risk factors, inadequate calcium intake and little exposure to sunlight, 
chronic corticosteroid or anticonvulsant drug use, endocrine disorders like primary 
hyperparathyroidism, type 1 diabetes mellitus or hyperthyroidism , anorexia nervosa, 
previous gastrectomy and pernicious  anaemia. A short fertile period (< 30 years) and 
surgical menopause were also implicated in the pathogenesis of impaired bone density 
(Espallargues et al., 2001).
 
 
The association between low BMI and an increased risk of fracture is well known as an 
adequate protein intake is needed to maintain the protein matrix in bone and the musculature 
that surrounds bone (De Laet et al., 2005).  
 
Ideally, bone mineral measurements should provide diagnostic criteria, determine fracture 
risk and be able to monitor patients for long term follow up. In a clinical environment, bone 
densitometry accurately predicts osteoporosis using dual energy X-ray absorptiometry 
(DXA). Historically, DXA measured BMD of the hip to generate a T-score. A single BMD 
test has a high specificity (approximately 85%) in the prediction of fracture risk, but lacks 
sensitivity (less than 50% of women with osteoporosis-related fractures have a BMD T-score 
in the osteoporosis range) (Hough et al., 2010).  
 
 
The World Health Organization (WHO) established criteria for assessing bone health and 
determining fracture risk. These criteria are defined by the T-score, which is the number of 
standard deviations (SDs) above or below the mean of the young adult group. Bone density is 
expressed as grams of mineral per square centimetre or grams per cubic centimetre. The T-
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score is calculated by comparing the current BMD of the woman to peak BMD of a normal 
adult Caucasian woman (aged 20-29 years). Osteoporosis has been defined as a T-score of  
< -2.5 SD. Severe osteoporosis is defined in the presence of a fracture. Osteopenia is a T-
score between 1.0-2.49 SD (WHO Technical report: series 921).  
 
A Z-score compares the patient’s bone mineral density with the mean value in a population 
of similar age, sex, and height (Richmond., 2003). This information is useful in determining 
the likelihood of secondary osteoporosis due to primary or secondary metabolic bone disease, 
infiltrating malignancies and drug-induced decreased bone mass. Z-scores are generally used 
in pre-menopausal women. A low Z-score   (-1.5 to -2.0) indicates a low bone mass and/or a 
rapid bone loss than that which is expected from an age-matched control (Hough et al., 2010).  
 
 
The National Osteoporosis Foundation has stated that bone mineral measurement alone is not 
a good predictor of fracture risk as the test has a high specificity (85%) but low sensitivity 
(Hough et al., 2010). Furthermore, they found that a large proportion of fractures are 
demonstrated, in women who fall, outside the WHO-defined osteoporotic T-score range. This 
finding was highlighted in a longitudinal study by Siris et al (2004) of 140,000 women with a 
mean age of 64.5 years. The study relied on the self-reporting of new fractures and was 
conducted over a period of 12 months. 2259 women reported new fractures during 1 year, but 
only 6.4% had a T-score that indicated osteoporosis (–2.5 SD). 
 
 
Current guidelines from the National Osteoporosis Foundation of South Africa (NOFSA) 
states that an integrated approach to the diagnosis and management of impaired BMD should 
be followed. Clinical risk factors are included in the assessment of osteoporosis-related 
- 21 - 
 
fractures. Non-modifiable risk factors for osteoporosis-related fractures include a personal 
history of fracture as an adult, history of fracture in a first-degree relative, white race, 
advanced age, female gender, dementia, and poor health/frailty. Modifiable risk factors 
include cigarette smoking, low body weight, estrogen deficiency, early menopause, 
prolonged premenopausal amenorrhea, low calcium intake, the use of bone toxic substances 
like glucocorticoids and alcohol, impaired eyesight despite adequate correction, poor 
health/frailty, recurrent falls, and inadequate physical activity (Hough et al., 2010).  
 
 
Some of these risk factors are partially or wholly independent of BMD (Hough et al., 2010). 
Independent risk factors used with BMD could, therefore, enhance the information provided 
by BMD alone. The consideration of well-validated risk factors, with or without BMD, is 




To date, the optimal frequency of screening for osteoporosis has not been determined (van 
der Klift et al., 2005).  
 
 
The International Society for Clinical Densitometry
 
and the National Osteoporosis 
Foundation (NOF) recommends BMD testing for all women aged ≥65 years or younger 
postmenopausal women with additional risk factors (Lewiecki et al., 2004).  
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The National Osteoporosis Foundation of South Africa (NOFSA) recommends that bone 
mineral density screening be performed on all women after the age of 65 years (Hough et al., 
2010). Furthermore, bone mineral density screening can be performed in younger women at 
any time in the presence of valid risk factors for an osteoporosis-related fracture. Routine 
follow up scans should be performed every 18-24 months. More regular scans may be 




The WHO is currently advocating an absolute risk assessment which may help to better 
identify and treat women in the future – The FRAX tool. 
The WHO FRAX
®
 tool evaluates the fracture risk of patients using the individual’s risks and 




The risk of fracture is calculated from gender, age, body mass index and independent risk 
variables like a prior fragility fracture, parental history of hip fracture, current tobacco 
smoking, long term use of oral glucocorticoids, rheumatoid arthritis, other causes of 
secondary osteoporosis and daily alcohol consumption of 3 or more units daily. 
In addition, femoral neck (hip) BMD, as a T-score, can be included in the calculation. This 
approach precludes BMD from being a primary determinant of fracture risk.  
 
 
Despite the promise associated with the FRAX model, there are limitations to it’s use.  
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To date, this integrated fracture risk model has not been adjusted for local conditions and 
therefore is not currently applicable to a South African population. Furthermore, Vitamin D 
deficiency, commonly associated with osteopaenia and osteoporosis, is not included in the 
risk assessment tool. 
 
 
Osteoporotic fractures are associated with major morbidity and impaired quality of life. With 
more people living to an older age, the financial and health-related costs of osteoporosis will 
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CHAPTER 1 
1.4 RELATIONSHIP BETWEEN CARDIOMETABOLIC PROFILE AND 
BONE MINERAL DENSITY 
 
Traditionally, cardiovascular disease and osteoporosis were considered distinct and unrelated. 
However, in a study by Mendelsohn et al (1999) “ a pathological link between calcium 
metabolism, the vascular system and blood coagulation” was suggested.  
 
An understanding of the cellular and molecular effects of oestrogen on both the 
cardiovascular system and bone allows one to appreciate the existence of a “cause-effect” and 
an “effect-effect” relationship between the two. 
 
Matrix proteins, such as type 1 collagen, proteoglycan, osteopontin, and osteonectin, are 
present in bone and vascular matrix components. These proteins play an important role both 
in bone formation and in the development of atherosclerosis. Endogenous oestrogen is 
associated with suppression of cytokines, such as IL-1, IL-6 and TNF-alpha and upregulation 
of osteoprotegerin. Thus in a hypo-oestrogenic state, there is an increase in these cytokines 
and a decrease in osteoprotegerin, both associated with bone loss and atherogenesis (Baldini 
et al., 2005).  
 
Endogenous oestrogen is seen as a cardio-protective hormone with a multimodal function. It 
has both immediate and long term effects on the cardiovascular system, with the long term 
benefits on blood vessel walls being better documented in the literature (Mendelsohn et al., 
1999) Furthermore, oestrogen replacement is associated with a 35 – 50% decrease in 
cardiovascular risk profile (Epstein et al., 1999).  
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The response of oestrogen to vascular injury and atherosclerosis remains one of the most 
important functions of the hormone (Mendelsohn et al.,1999). Oestrogen induces vasodilation 
and affects the fibrinolytic-coagulation pathway, promoting fibrinolysis (Harvey.,1999). 
Further effects on the coagulation and fibrinolytic systems occur with hepatic gene regulation 
of antithrombin 3, Protein S and fibrinogen concentrations (Mendelsohn et al.,1999).  
 
 
The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial examined the effects of 
oestrogen or oestrogen/progestin regimens on heart disease risk factors in menopausal 
women. The trial found that oestrogen alone or in combination with a progestin improves 
serum lipoprotein levels and lowers fibrinogen levels without detectable effects on insulin or 
blood pressure (Bush., 1995) 
 
 
Oestrogen is also associated with endothelial cell growth (Morales et al.,1995). Vascular 
Endothelial Growth Factor (VEGF) promotes re-endothelialization, inhibiting endothelial 
apoptosis and enhancing the vascular system’s response to injury. This results in inhibition of 
smooth muscle proliferation within the vascular system and the promotion of endothelial cell 
growth. Additionally, 17ß oestradiol has been shown to have beneficial antioxidant effects in-
vivo (Morales et al., 1995). 
 
Mendelsohn et al (1999) found that oestrogen promotes vasodilation by down-regulating the 
expression of angiotensin 2, and thereby, the Renin Angiotensinogen System (RAS) and 
Endothelin 1. With decreases in endothelin 1, the resultant ratio between NO and endothelin 
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increases.  This increase allows for a greater bioavailability of endothelial derived NO, 
favouring relaxation of vascular smooth muscle.  
 
 
Normal bone turnover involves a balance of bone resorption (by osteoclastic acidification and 
proteolytic digestion of old bone) and bone formation (by osteoblastic laying down of osteoid 
within the resorptive cavity). In older women, the bone remodeling process becomes 
progressively inefficient due to the hypo-oestrogenic state that characterises the menopause.  
Oestrogen withdrawal during menopause is associated with a protracted lifespan of 
osteoclasts and early osteoblast cell death resulting in bone loss (Mendelsohn et al., 1999).   
 
 
Early evidence from Browner et al (1993) suggested an association between cardio-metabolic 
profile (which included atherosclerotic vascular disease, hypertension, dyslipidaemia and 
altered glucose metabolism) and low BMD. This relationship was demonstrated despite a 
comparable distribution of baseline cardiovascular risk factors amongst women. 
 
 
Further support of this relationship was demonstrated by Barengolts et al (1998) who 
compared coronary calcium scores in 45 asymptomatic postmenopausal women with normal 
and low BMD. Coronary calcium scores were measured using electron beam computed 
tomography of the heart and BMD of the lumbar spine and proximal femur was measured by 
dual X-ray absorptiometry. The study demonstrated that oestrogen deficiency is a risk factor 
for osteoporosis and coronary artery disease. Furthermore, high coronary calcium scores in 
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patients with pre-existing osteoporotic vertebral fractures, correlated with an increased risk of 
coronary and aortic artery calcification and a higher prevalence of ischaemic heart disease. 
 
 
Marcovitz et al (2005) was the first study to report osteoporosis as a predictor of coronary 
artery disease (CAD) in the postmenopausal population, with a low bone mineral density 
associated with significant CAD in females. Varma et al (2008) further demonstrated that the 
prevalence of obstructive CAD (diagnosed on angiogram following chest pain) was greater in 




Studies performed in Denmark on postmenopausal women demonstrated an increased 
incidence of cardiovascular events and a two fold increase in cardiovascular mortality in 
patients with confirmed low bone mineral density (Von der Recke., 1999). 
 
 
A further evaluation of approximately 2500 postmenopausal women (mean age, 66.5 years) 
with osteoporosis demonstrated that these women were at an increased risk for cardiovascular 
events (Tanko et al., 2005). This risk was proportional to the severity of osteoporosis at the 
time of the diagnosis. When compared to low bone mineral density, women with osteoporosis 
had a 4-fold increased risk for cardiovascular events. Furthermore, the presence of at least 
one vertebral fracture at baseline was associated with a 3.0-fold increase in risk. This risk was 
proportional to the number and severity of baseline vertebral fractures. 
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Bansel et al (1992)
 
found that low calcium concentrations were associated with an up-
regulation of parathyroid hormone (PTH), and a paralleled increase in tissue plasminogen 
activator (by osteoblasts). PTH has been likened to a hypertensive factor and is implicated in 
the pathophysiology of hypertension in the postmenopausal patient (Hoekman et al, 1991). 
Furthermore, PTH is seen to have local effects on bone demineralization and systemic effects 
on atherosclerotic vascular disease, hypertension and coagulopathy (Maillard et al., 1992).  
 
                          
This thread is further supported by a study by Browner et al (1993) were the unfavourable 
pattern of calcitrophic hormones (decreased Vitamin D metabolism and renal dysfunction 
with increased action of PTH) not only had negative implications on bone, but affected 
vascular reactivity. 
 There have also been suggestions that hypertension may be associated with low bone mineral 
density in the elderly, with BMD being inversely proportional to systolic blood pressure 
(Tsuda et al., 2001). 
 
 
Low bone mineral density has been associated not only with an increased risk for stroke 
(relative risk of 1.3 per standard deviation below mean BMD), but has been shown to be a 
possible predictor of the first onset of stroke in postmenopausal women, independent of age 
(Browner et al (2003). Jorgensen et al (2001) demonstrated that women in the lowest quartile 
for BMD had a greater risk for stroke than those in the highest quartile (an odds ratio of 4.8 
or an increase in odds ratio by 1.9 per standard deviation reduction in BMD). 
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A Swedish population-based cohort study of twins by Sennerby et al (2009) investigated the 
relationship between CVD and risk of hip fractures. More than 30 000 twins were followed 
up over a 50 year period. Following the diagnosis of peripheral atherosclerosis, there was a 3 
times greater risk of a hip fracture. The risk of a hip fracture was 4 times greater following 
cardiac failure and 5 times greater after a stroke. The study demonstrated increased rates of 
hip fracture after different major cardiovascular events, and supports the hypothesis of a link 
between cardiovascular disease and bone health. 
 
 
An additional link between cardiovascular disease and osteoporosis seems to be related to the 
action of some drugs, such as bisphosphonates, statins and raloxifene. Studies suggest that the 
mechanism of action of these drugs at cellular level may not be mutually exclusive, acting 
either in bone or in atherosclerotic plaque.  
 
 
A meta-analysis by Uzzan et al (2007)
 
has shown a beneficial link between statins and hip 
BMD. The implications thereof are that statins not only play a role in decreasing 
atherogenesis, but may be associated with decelerated bone loss. Varma et al (2008) gave 
further relevance to this by demonstrating that 86% of postmenopausal patients maintained 
normal BMD on statins.  
 
 
A current survey of the literature demonstrates no consensus regarding the relationship 
between lipid profile and bone mineral density (Bagger et al., 2005, Yamaguchi et al., 2002, 
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D’Amelio et al., 2008, Makovey et al., 2009). Bagger et al (2005) conducted a study on the 
lipid profile in postmenopausal women in Denmark. The study population included 
postmenopausal women from the PERF study (Prospective Epidemiological Risk Factors 
Study).  Yamaguchi et al (2002) conducted a similar study, but on Asian postmenopausal 
women in Japan. Both studies found that low triglyceride levels were independently 
associated with vertebral fractures. These studies favour the assumption that a pro-
atherogenic profile is associated with a higher bone mineral density. 
 
In a cross sectional study by D’Amelio et al
 
(2008) on Italian postmenopausal women, a 
higher level of HDL cholesterol was associated with higher rates of osteoporosis in normal 
weighted postmenopausal women. Yamaguchi et al
 
(2002) showed that plasma LDL 
cholesterol levels were significantly and inversely correlated with the absolute values of 
radial and lumbar BMD in Japanese postmenopausal women. Furthermore, Makovey et al 
(2009) conducted a study on postmenopausal Caucasian women in Sydney, Australia. They 




The association between low BMI and an increased risk of fracture is well known as an 
adequate protein intake is needed to maintain the protein matrix in bone and the musculature 
that surrounds bone (De Laet et al., 2005).  
 
Zhao et al (2007) evaluated the relationship between obesity and osteoporosis in more than 
3000 Caucasian and Chinese postmenopausal women. Whole body fat mass, lean mass, 
percentage fat mass, body mass index, and bone mass was measured in each ethnic group The 
study demonstrated that bone mass was proportional to fat mass in both Asian and Caucasian 
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women. The findings of this study were explained by the association between high oestrogen 
levels and obesity, with resultant decrease in osteoclastic activity, possible increased 
osteoblastic activity and subsequent increased bone mass. 
 
Finkelstein et al (2008) and Zhao et al (2007) support the assumption that ethnicity and body 
weight are powerful independent predictors of baseline bone density, and affected the rate of 
bone mineral loss and fracture risk.  These disparities may be reflected by a difference in the 




 In a randomised controlled trial by Hyun et al (1992), women who had modest weight loss 
had lower bone mineral densities. Finkelstein et al (2008) demonstrated that lumbar spine 
bone mineral density loss was accelerated in the underweight postmenopausal women. In this 
study, it was demonstrated that the average African female weighs 9kg more than the average 
Caucasian, and up to 26 – 27kg more than the average Asian. Furthermore, Kadam et al 
(2010) found that Asians showed the most rapid deterioration in bone mineral density 
followed by Caucasians and the Africans. This may explain why osteoporosis is found to be 
most severe in Caucasians and Asians, and least severe in African women. 
 
 
Cardiovascular disease and osteoporosis are public health problems with numerous 
epidemiological links and important economic consequences. These two conditions may be 
sustained by similar or common pathophysiological mechanisms and risk factors. However, 
further studies are necessary to define the relationship between the two entities more 
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specifically and to understand the complex interaction of similar or common risk factors and 
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CHAPTER 1 
1.5 MANAGEMENT OF THE MENOPAUSE 
1.5.1 CARDIO-METABOLIC RISK 
 
Coronary artery disease is multifactorial, with gender specific differences in the 
epidemiology, diagnosis, prognosis and management (International Menopause Society 
Consensus statement, 2009).
   
 
 
Adverse changes in lipids and lipoproteins are associated with the onset of menopause. 
Derangements in lipid profile include increases in total cholesterol, LDL and triglycerides, 




Changes in glucose and insulin metabolism that hallmark the menopause are pivotal in the 
pathogenesis of cardiovascular disease (Stevenson et al., 1995; Walton et al., 1993). Diabetes, 
alone, is associated with a four-fold increase in the incidence of cardiovascular disease 
(Winkler et al., 1992).
 
An android fat deposition, associated with menopause, further 
promotes the metabolic derangements in lipids, glucose and insulin (Gorodeski., 2002).   
 
 
In addition, the reduction in fibrinolysis and increased coagulant activity tips the balance 
towards a pro-coagulant environment in the menopausal years (Gorodeski., 2002). 
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Women should be screened for diabetes mellitus, hypertension, hypercholesterolaemia and 
metabolic syndrome during the menopause and be managed, where possible, by a multi-
disciplinary team. Conroy et al (2003)
 
developed the SCORE chart which estimates the ten 
year risk of fatal cardiovascular disease in low and high risk populations. Non modifiable 
cardiovascular risk factors like age, family history and ethnicity are coupled with modifiable 
risk factors like blood pressure, plasma cholesterol, LDL and HDL levels, diabetes or glucose 
intolerance, body weight and cigarette smoking. The SCORE chart is crucial in the 
appropriate risk stratification of the postmenopausal women which allows for the optimal 
intensity of patient management.  
 
 
The most effective reduction in cardiovascular events is primary prevention (Conroy et al., 
2003). Thus, lifestyle factors, which include a diet rich in high saturated fats, avoiding 
smoking and excessive alcohol intake and physical inactivity, play a pivotal role in the 
pathogenesis of cardiovascular disease (Gorodeski., 2002).  
 
 
Body weight and central obesity is directly linked to cardiovascular risk and mortality rates 
with weight loss resulting in improved cardiovascular risk factors such as abdominal 




Diet and physical exercise are highly effective in reducing the incidence of metabolic 
syndrome and the risk of diabetes mellitus, with regular physical exercise (≥ 30 minutes on 
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most days of the week) decreasing cardiovascular risk by 75% (Godstein et al., 2000). A 
healthy diet should include the ‘five-a-day guideline of fruit and vegetables, whole-grain 
cereals and breads, low fat diary, lean meat and fish. Judicious salt intake (<1 teaspoon per 
day) and limited cholesterol intake (<300mg daily) should be highlighted (Gorodeski., 2002). 
The detrimental effects of smoking should be highlighted and smoking cessation strategies 
should be employed (Conroy et al., 2003).  
 
 
In conjunction with a specialist physician, appropriate anti-hypertensives should be instituted 
with strict blood pressure monitoring. The target for optimal blood pressures in the non-
diabetic patient is <140mmHg systolic and <90mmHg diastolic (Conroy et al., 2003). This 
target drops to <130mmHg systolic and <80mmHg diastolic in the diabetic or a patient with 
chronic renal disease (Conroy et al., 2003).
 
 
Total plasma cholesterol is a prime concern in the prevention of cardiovascular disease (De 
Backer et al., 2003). Target levels include <5mmol/L in the non-diabetic and <4.5mmol/L in 
the diabetic or women with established cardiovascular disease. Serum LDL levels should be 
maintained at <2.5mmol/L in the high risk population (De Backer et al., 2003). 
 
 
To date there are no specific treatment goals for HLD and triglycerides, but fasting levels can 
be used as a marker for dyslipidaemia. The initiation of statins should be a combined decision 
between the cardiologist and gynaecologist. To date, there is no firm evidence that low dose 
aspirin or statins are as effective in women with established cardiovascular disease as they are 
in men (Conroy et al., 2003). 
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Hormone replacement therapy in menopausal women is widely accepted as the gold standard 
for the amelioration of distressing vasomotor symptoms in the menopause.                                                                                     
However, oestrogen replacement has also been associated with favourable cardio-metabolic 
profile in both observational and randomised controlled trials (Rymer and Morris.,  2000, 
MacLennan et al., 2001).  
 
Total collagen declines approximately 2.1% per menopausal year over 15 years (Calleja-
Aguis et al., 2009). While a decline in collagen is usually associated with troublesome skin 
symptomatology, the true danger lies in the effect on arterial vasculature. The arterial system 
is anatomically composed of the tunica intima, tunica media and tunica externa. In the 
menopause, there is progressive loss of connective tissue from within the tunica media. This 
eventuality is compounded by the associated thickening of the tunica intima by 
atherosclerotic plaques (Speroff et al., 2005).  
 
Oestrogen has profound effects on connective tissue turnover, irrespective of the site, and has 
been shown to prevent tunica media loss. Baron et al (1998) and Sator et al (1998)
 
have 
shown that oestrogen therapy users had a statistically significant greater thickness in the 
tunica media than those who did not (0.34mm versus 0.27mm). The mean carotid artery wall 
measurement was 0.76mm in the treated group and 0.70mm in the untreated group (Sator et 
al., 1998). Furthermore, the intima media ratio was significantly higher in the treated group 
(Sator et al., 1998).  
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Tremollieres et al (2000) noted that this protective effect of oestrogen on the tunica intima-
media ratio was only found in older postmenopausal women, and unlikely to occur before age 
55 years. 
 
The effect of progestin on the vasculature is still uncertain. Liang et al (1997) has shown that 
progestins have no effect on tunica intima-media thickness but may have deleterious effects 
on arterial stiffening. 
 
Godstein et al (2000) reported an 11% risk reduction for primary cardiovascular disease in 
postmenopausal women using hormone therapy compared with women who had never used 
hormone therapy, irrespective of duration of use (Godstein et al., 2000). This risk reduction 
was noted soon after initiation of treatment and sustained for up to 10 years of use. 
 
Initiating oestrogen therapy in the immediate peri- or postmenopause is therefore believed to 
limit the development of atherosclerosis. However, the initiation of oestrogen therapy cannot 
reverse established arterial damage from pre-existing atherosclerosis (Gorodeski et al., 2002).
  
 
While alternative therapies are considered to be the safer, more natural option for the modern 
day women (Rees., 2009), there is limited research regarding it’s safety and benefit when 
compared to conventional hormonal therapies (RCOG opinion paper 2006, British 
Menopause Society Council statement, 2007). Examples of botanicals include phyto-
oestrogens (soy and red clover), black cohosh, evening primrose, dong quai, ginseng and 
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many chinese herbs. The evidence regarding botanicals, vitamins and homeopathy is scant, 
with very little well-designed research. Furthermore, these agents are not regulated by any 
drug administration, resulting in various chemical compositions with unknown side effects 
(including malignancy) (Rees et al., 2009). With increasing concern over the anticipated 
detrimental effects, well designed randomized controlled trials should be performed before 
the clinician can safely recommend the use of an agent in the menopause.  
 
 
1.5.2 BONE MINERAL DENSITY 
 
Osteoporosis is a silent disease with little morbidity or mortality until the first fracture occurs 
(Sturdee et al., 2009). Undoubtedly, prevention of fractures should be the mainstay of 
treatment protocols.  
 
Normal body homeostasis is regulated by the maintenance of normal serum calcium. In the 
event of hypocalcaemia, stores are mobilized from bone, under the action of parathyroid 
hormone, thus resulting in bone fragility (De Villiers., 2009). Calcium and vitamin D 
supplementation is required for a women to attain genetically determined peak bone mass and 
then maintain bone mass and strength (Tang et al., 2007). A recent meta-analysis by Tang et 
al (2007) with fractures as outcomes found that calcium supplementation is associated with a 
12% reduction in all types of fractures in people aged 50 years. In patients with 80% 
compliance, fractures were reduced by 24%.  
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Over the recent years, vitamin D supplementation has sparked much interest and research. 
Vitamin D is essential to the absorption of calcium. Furthermore, the North American 
Menopause Society has stated that low vitamin D is associated with impaired muscle 
strength, more falls and higher rates of fragility fractures. Many postmenopausal women 
become bed-bound and, with age-related inability of the skin and renal system to produce 
active Vitamin D, many elderly will have grossly inadequate serum vitamin D levels (De 
Villiers., 2009). Vitamin D serum levels can be directly measured the blood level of 25-
hydroxyvitamin D, and indirectly by observing the inverse relationship with the level of 
parathyroid hormone.  
Current recommendations from the International Menopause Society include calcium (1 gram 
daily) and vitamin D (800IU daily), with no consensus on any other food supplementation. 
 
 
Interventional programmes and counselling should be directed towards smoking cessation 
and excessive alcohol consumption.
 
Jenkins et al (2008) found
 
that smoking, or more 
specifically, the nicotinic effects of smoking, have been linked to impaired hip bone density. 
So too does the consumption of large amounts of alcohol. A careful history of high dose 
glucocorticoids should be attained and cessation of unnecessary steroid use should ensue. 
High dose steroid use has been demonstrated to have deleterious effects on BMD from 
initiation, with the peak effect attained after 6 months on treatment (de Nijs et al., 2008). This 
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The North American Menopause Society recommends strength training in the early 
menopause (North American position statement 2010: Management of osteoporosis in 
postmenopausal women). Strength training, done twice weekly, was associated with a 2% 




Fall prevention is pivotal in the general management of a patient with impaired BMD 
(Campbell et al., 2004). In a study by Campbell et al (1994) tapering or cessation of 
neuroleptics, sedatives and antidepressants were shown to reduce the risk of a fall by 60%. 
The North American Menopause Society has outlined various inexpensive measures to 
eliminate safety hazards in the home. These are highlighted in the table 2 below. Parker et al 
(2005) found that the use of hip protectors, to reduce hip and pelvic fractures in the event of a 
fall, have not been borne out by conclusive evidence. 
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Table 2: Fall prevention strategies (North American Menopause Society) 
 
LIGHTING  
1. Provide ample lighting 
2. Have easy to locate light switches 
3. Illuminate walkways with night lights 
OBSTRUCTIONS 
1. Remove clutter, low-lying objects 
2. Remove raised door sills 
 
FLOORS AND CARPETS 
1. Provide non-skid rugs on slippery floors 
2. Repair/replace worn out carpet 
3. Use nonskid floor wax 
 
FURNITURE 
1. Arrange furniture to ensure clear pathways 
2. Remove or avoid low chairs and armless chairs 
3. Adjust bed height if too high or too low 
 
STORAGE 
1. Install shelves and cupboards at accessible height 




1. Install grab bars in shower, bathrrom, toilet 
2. Use chair in shower and tub 
3. Install nonskid strips 
4. Elevate low toilet seat and install safety frame 
 
STAIRWAY AND HALLS 
1. Install handrails on both sides of stairs 
2. Remove or tape down rugs 
3. Repair loose or broken steps 
4. Install nonskid treads on steps 
North American Menopause Society Position Statement 2010 
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Pharmaco-therapeutic interventions available for the prevention of fractures are classified as 
those that inhibit bone resorption (HRT; Bisphosphonates and selective oestrogen receptor 
modulators - SERMS), those that stimulate bone formation (Teriparitide) and a combination 
of the two (like Strontium Ranelate) (Maclean et al., 2008). There are very few studies that 
compare the efficacy and safety of these therapies (Maclean et al., 2008).  Choice of use is 
therefore based on the individual’s decision based on the studies for a particular drug, cost 
and compliance. 
 
Oestrogen is known to inhibit osteoclastic activity and result in osteoclast apoptosis (Krassas 
and Papadopoulou., 2001). Oestrogen is also associated with positive effect on calcium 
balance (De Villiers et al., 2009).  
 
The role of progesterone in bone turnover is still unclear but Fujimaki et al (1995) and Liang 
et al (2003) have shown that progesterone has an effect on bone proliferation and inhibition 
of bone resorption.  
 
 
The Women’s HOPE study, by Lindsay et al (2002), was a two-year randomised, double-
blind, placebo-controlled sub-study of the Women’s Health, Osteoporosis, Progestin, 
Estrogen trial, conducted at 19 centres in the United States. More than 800 post-menopausal 
women participated in the trial. The study demonstrated that doses as little as 0.3 mg/d 
oestrogen, with or without medroxyprogesterone acetate, increased BMD at the hip and spine 
(Lindsay et al., 2002). It is not known as to whether this finding can be associated with a 
reduction in fracture risk. 
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Following the results from the Women’s Health Initiative (WHI), long term use of HRT in 
the elderly became unacceptable as the risk for venous thromboembolism, cardiovascular 
events, stoke and breast cancer were reported as being appreciably higher (Jackson et al., 
2006).  The International Menopause Society suggests that HRT, at the lowest effective dose, 
can be used in younger menopausal women with vasomotor symptoms and a current fracture 
risk with replacement by another agent after the age of 60 years. HRT should not be used as 
the first line of therapy for osteoporosis (Sturdee et al., 2009). 
 
Bisphosphonates have the most extensive track record in osteoporosis therapy and are widely 
used. They inhibit osteoclastic activity by blocking the mevalonic pathway (De Villiers., 
2009) Examples include Alendronate, Etindronate, Risedronate, Ibandronate and Zoledronic 
acid. The level of suppression of bone turnover varies with each preparation, but the effect of 
osteoclastic suppression continues with all agents after cessation of use. The necessary 
duration of therapy is currently unknown.  
 
 
Studies like those of Colon-Emeric et al (2006) recommends the cessation after 5 years of use 
in a patient with a T-score > -3.5 and no current risk factors for fracture. The drug has often 
been associated with oesophageal irritation and gastro-oesophageal reflux, thus requiring a 
strict protocol for ingestion (Gertz et al., 1995). Furthermore, absorption is less than 1% of 
the oral dose
 
and bioavailability is easily impaired by ingestion of liquids other than plain 
water or by eating or drinking too soon after taking the bisphosphonate. There have also been 
studies linking bisphosphonates with osteonecrosis of the jaw (Woo et al., 2006). 
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The majority of patients taking oral bisphosphonates have a weekly or monthly dosing, with 
studies by Recker et al (2005) and Cooper et al (2006) showing that adherence to therapy is 
better, but still suboptimal, with intermittent dosing.  
 
 
Raloxifene is currently the only available selective oestrogen receptor modulator. Other 
preparations include Lasofoxifene, Bazedoxifene and Arzoxifene. The Multiple Outcomes of 
Raloxifene Evaluation (MORE) study was a multi-centre, randomized, blinded, placebo-
controlled trial on over 7000 women aged 31 to 80 years in 25 countries. The MORE trial by 
Ettinger et al (1999) demonstrated that Raloxifene was associated with increases in spine and 
femoral neck bone mineral density and a risk reduction in vertebral fractures.
 
There are no 
significant endometrial effects, but may exacerbate vasomotor symptoms.  
 
 
The Raloxifene Use for The Heart (RUTH) trial, examined the effect of Raloxifene on risk 
reduction for coronary heart disease in postmenopausal women (Barret-Connor et al., 2006). 
The study demonstrated that Raloxifene did not reduce this risk of a coronary event.  
Raloxifene was found to increase the risk for venous thromboembolism by 44% and fatal 
stroke by 49%, although no significant differences were seen in rates of death or total strokes. 




Teriparatide, a recombinant human parathyroid hormone, is a pure anabolic agent which 
stimulates new cortical and trabecular bone development. Teriparatide was shown to reduce 
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the risk for vertebral fractures by 65% and non-vertebral fractures by 53% in treatment naïve 
women, but was associated with concern regarding increased osteosarcoma risk in rats in a 
study by Neer et al (2001).To date this fear has not been substantiated in humans. Side effects 
are usually minimal and include headaches, nausea and muscle cramps, associated with mild 
hypercalcaemia. The drug is limited by its cost and method of administration (a subcutaneous 
daily dosing). Indications for use include patients with severe osteoporosis or the presence of 
new fractures despite compliance on another antiresorptive agent (Hough et al., 2010). 
 
 
Strontium ranelate has a dual action in reducing bone resorption and increasing formation by 
acting on the RANK ligand system and calcium sensitive receptors (Chattopadhyay et al., 
2007). It is packaged as a powder and taken as a daily dose in a water suspension. Studies by 
Meunier et al (2004) and Reginster et al (2005) have demonstrated increases in BMD with a 
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CHAPTER 2 




To assess the cardio-metabolic risk profile and incidence of low bone mineral density in 
Indian and African postmenopausal women attending the Inkosi Albert Luthuli menopause 
clinic and to determine whether there is a correlation between cardio-metabolic parameters 
and low bone mineral density. 
 
METHODS                                     
This study was a retrospective, descriptive audit. 
 
After institutional ethical approval was obtained, all Indian and African postmenopausal 
women, above the age of 40, referred to the gynaecology menopause outpatient clinic at 
Inkosi Albert Luthuli Central Hospital (IALCH) from 01 July 2009 to 31 December 2010 
were recruited into the study.  
 
 
IALCH is a large tertiary referral hospital for the province of Kwa-Zulu Natal serving mainly 
an indigent population. The gynaecology menopause clinic at IALCH was formally 
established in June 2009. Women are referred to the menopause clinic from the surrounding 
regional hospitals and other outpatient clinics at IALCH (urogynaecology, general 
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gynaecology and other medical disciplines). Women with natural or surgical menopause are 
referred to the clinic. 
 
 
All women, attending the menopause clinic, are assessed on the primary consultation and 
their demographic and clinical data are entered onto a primary assessment form. The results 
of biochemical and radiological investigations are entered onto this form as they are 
completed. All consultations at IALCH are stored in the medi-com database. 
 
 
Menopause was defined as amenorrhea for more than 6months with a serum FSH> 30IU/L or 
amenorrhea for more than 12 months. African or Indian postmenopausal women above the 
age of 40, with confirmed menopause were included in the study. Women with premature 
ovarian insufficiency (in women <40years), peri-menopausal women, patients with a 
Follicular Stimulating Hormone (FSH) levels < 30IU/L and women with decreased bone 
mineral density from pre-existing chronic disease were excluded from the study. A sample 
size of at least 50 women from each race group was required, as determined by a statistician. 
 
 
Ethical and institutional approval was obtained from the Biomedical Research Committee, 
Inkosi Albert Luthuli Central Hospital and Natalia prior to the initiation of data collection.             
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Participant data were collected retrospectively from the IALCH medi-com database using a 
structured questionnaire. There was no direct patient contact and all information was kept 
confidential. The information required to complete the questionnaire was found on the 
primary assessment form. 
 
 
Demographic data included age, ethnicity and years since the final menstrual period. The data 
analysed included the presence of menopausal symptoms, a history of hypertension, diabetes, 
ischaemic heart disease, hypercholesterolaemia, impaired bone mineral density or previous 
fragility fracture. A family history of the same parameters was assessed. A previous history 
of gestational diabetes, past pre-eclampsia and confirmed polycystic ovarian syndrome was 




Clinical data included systolic and diastolic blood pressure, height and weight, abdominal and 
hip circumference, calculated body mass index, calculated waist hip ratio, clinical stigmata 
for dyslipidaemia and insulin resistance. 
 
 
Biochemical investigations included a fasting lipogram (cholesterol, triglycerides, HDL and 
LDL), fasting glucose and insulin levels and thyroid function tests.  
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Radiological investigations included dual energy absorptiometry (DEXA) of the hip and 




TSH was analysed using a chemiluminescent assay. Serum glucose was analysed using the 
Hexokinase 2 step method which produces a solution that absorbs ultraviolet light. The 
absorbance of the solution is proportional to the glucose concentration. Total cholesterol and 
triglyceride specimens were analysed using 2-point kinetic enzymatic assays. The intra- and 
inter-assay coefficients for TSH were 11.2% and 9.5%; 10.2% and 7.9% for fasting insulin; 
6.9% and 3.4% for fasting glucose; 5.6% and 2.9% for triglycerides;  5.9% and 1.2% for 
cholesterol and 8.4% and 9.9% for HDL. These assay coefficients were calculated with the 
normal values of the respective metabolites in mind, namely 11-22.7 pmol/L for T4; 0.27-4.2 
mIU/L for TSH; 3-25 mIU/ml for fasting insulin; 3.8-5.3 mmol/L for fasting glucose; <5.8 
mmol/L for cholesterol; <2.83 mmol/L for trigylcerides; <1 mmol/L for HDL and <2.6 





Cardio-metabolic data were analysed as continuous variables and summarized using 
frequencies, percentages, means and standard deviations. Bone mineral density was treated as 
a quantitative variable and correlation analysis was used to assess relationships between the 
variables. This was done for each race group separately. The Pearson Chi
2
 test was used to 
determine associations between two categorical variables. ANOVA was used to assess the 
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difference in means between the two ethnic groups. The Independent Students T-test was 
used to compare cardio-metabolic variables between the two race groups. For multiple 
comparisons, Bonferroni adjusted statistics was used. The significance level was set at 0.05. 



























A total of 137 women attended the menopause clinic from 01 July 2009 to 31 December 
2010. These included 55 African women, 61 Indian women, 18 Caucasian women and 3 
Coloured women. The charts of 116 menopausal women attending the IALCH menopause 
clinic were analysed from 01 July 2009 to 31 December 2010. These charts comprised 55 
African and 61 Indian women. Ten women were excluded from further analysis as they did 
not meet the inclusion criteria (6) or had missing data (4). This resulted in a sample size of 55 
Indian and 51 African women in the study.  
 
This was a retrospective chart review, negating any patient contact.  
 
The demographic profile is displayed in Tables 3 and 4. The mean age of postmenopausal 
women was 60 years and 58 years for Indian and African women respectively. The mean 
duration after the FMP was 10 years for Indian women and 8 years for African women. There 
were no statistical differences between Indian and African women with regards to age and 
duration after FMP.                   
                                                               
The presence of vasomotor symptoms was reported in 70.6% of African women and 61.8% 
of Indian women. The presence of urogenital symptoms was reported in 54.9% of African 
women and 61.8% of Indian women. This difference was not statistically significant. 
Significantly more Indian women (50.9%) used HRT preparations when compared to African 
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women (23.5%). Very few African women (3.9%) and Indian women (3.6%) used 
alternatives to HRT. 
 
A significant number of women attending our menopause clinic had co-morbidities; 60% had 
hypertension, 44% diabetes, 10% ischaemic heart disease and 25% had dyslipidaemia. A 
previous history of pre-eclampsia and gestational diabetes was reported in 6% and 5% of 
women respectively. Indian postmenopausal women reported a higher prevalence of 
hypertension, diabetes, dyslipidaemia, ischaemic heart disease and low bone mineral density 
when compared to African postmenopausal women. However, there were no statistical 
differences for any of the risk factors in either ethnic group.                 
                   
                                                           
TABLE 3: Demographic profile (Mean and SD*) of African and Indian postmenopausal 
women 
 AFRICAN (n=51) INDIAN (n=55) p value 
 Mean  (SD)* Mean  (SD)*  
Age 58 (11) 60 (9) 0.19 
Years since FMP 8 (8) 10 (9)  
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TABLE 4: Demographic profile (n and %) of African and Indian postmenopausal 
women 
 AFRICAN (n=51) INDIAN (n=55) p value 
 n (%) n (%)  
Hypertension 28 (54.9) 36 (65.5) 0.27 
Diabetes mellitus 16 (31.4) 31 (56.4) 0.19 
Ischaemic heart disease 3 (5.9) 8 (14.9) 0.21 
Dyslipidaemia 9 (17.6) 18 (32.7) 0.08 
Osteopaenia/Osteoporosis 12 (23.5) 22 (40) 0.07 
Smoking 7 (13.7) 2 (3.6) 0.06 
Alcohol intake 3 (5.9) 1 (1.8) 0.27 

















HRT 12 (23.5) 28 (50.9) <0.001 
HRT alternatives 2 (3.9) 2 (3.6) 0.93 
Vitamin D supplements 4 (7.8) 6 (10.9) 0.59 
Calcium supplements 29 (56.9) 13 (23.6) 0.03 
Antiresorptive agents  2 (3.9) 11 (20) 0.01 
 
The majority of women (90%) ate a mixed diet and 68% led an inactive lifestyle. Social 
habits including alcohol intake and smoking were reported in 8% and 3% respectively. There 
were no statistical differences amongst the African and Indian women regarding diet, lifestyle 
and social habits. 
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Significantly more Indian women (20%) used antiresorptive agents compared to African 
women (3.9%) while significantly more African women (56.9%) used calcium 
supplementation compared to Indian women (23.6%).  
 
Tables 5 and 6 illustrate the clinical profile of African and Indian women attending the 
IALCH menopause clinic.  
 
TABLE 5: Clinical profile (Mean and SD) of African and Indian postmenopausal 
women 
 
 AFRICAN (n=51) INDIAN (n=55) p value 
 Mean (SD) Mean (SD)  
Height (cm) 158 (8) 155 (7) 0.12 
Weight (kg) 84 (20) 69 (15) <0.001 
BMI* (kg/m2) 33 (7) 29 (7) 0.01 
WHR** 0.88 (1.03) 0.84 (0.09) 0.08 
SBP‡ (mmHg) 143 (24) 148 (24) 0.21 
DBP† (mmHg) 77 (14) 81 (13) 0.12 
*BMI: Body mass Index                                     **WHR: Waist Hip ratio    
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TABLE 6: Clinical profile (n and %) of African and Indian postmenopausal women 
 AFRICAN (n=51) INDIAN (n=55) p value 
 n (%) n (%)  
Xanthoma 10 (19.6) 9 (16.4) 0.67 
Xanthelasma 5 (9.8) 7 (12.7) 0.64 
Arcus senalis 2 (3.9) 1 (1.8) 0.52 
Acanthosis 
nigricans 
5 (9.8) 7 (12.7) 0.64 
 
 
The weight and mean body mass index (BMI) of African women was significantly higher in 
African women when compared to Indian women, with 86.3% of African women and 78.2% 
of Indian women having a BMI of greater than 25 (shown in Table 7). Significantly more 
African women had a BMI of greater than 30. There were no differences in height, WHR, 
SBP, DBP, clinical stigmata of dyslipidaemia or insulin resistance between African and 
Indian postmenopausal women. 
 
TABLE 7: BMI of African and Indian postmenopausal women 
 AFRICAN (n=51) INDIAN (n=55) p value 
BMI (kg/m2) n (%) n (%)  
19-25 7 (13.7) 12 (21.8) 0.21 
25-30 9 (17.6) 21 (38.1) 0.06 
>30 35 (68.7) 22 (40.1) 0.04 
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Table 8 demonstrates the biochemical parameters of African and Indian postmenopausal 
women. There were no statistically significant differences amongst African and Indian 
postmenopausal women with regards to the analyzed biochemical parameters. 
 
TABLE 8: Biochemical profile† (Mean and SD*) of African and Indian postmenopausal 
women 
 AFRICAN (n=51) INDIAN (n=55) p value 
 Mean (SD) Mean (SD)  
Cholesterol (mmol/L) 5.69 (1.49) 5.90 (0.97) 0.38 
Trigylcerides (mmol/L) 2.15 (1.44) 2.30 (1.31) 0.38 
HDL cholesterol 
(mmol/L) 
1.36 (0.33) 1.46 (0.41) 0.32 
LDL cholesterol 
(mmol/L) 
3.20 (0.89) 3.37 (0.91) 0.36 
Insulin (mIU/ml) 16.40 (6.30) 18.50 (11.60) 0.75 
Glucose (mmol/L) 7.20 (2.60) 7.70 (2.60) 0.35 
Thyroxine (pmol/L) 13.10 (2.61) 13.82 (2.16) 0.12 
*SD: Standard deviation 
†normal values available in appendix C 
 
 
Table 9 represents the lipid profile of African and Indian postmenopausal women. The 
majority of women had an abnormal lipid profile; 53% of African women and 73% of Indian 
women demonstrated abnormal cholesterol, 22% of African women and 27% of Indian 
women had abnormal triglyceride profiles, 82% of African women and 80% of Indian women 
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demonstrated abnormal LDL-cholesterol profiles and 94% of African women and 98% of 
Indian women demonstrated abnormal HDL-cholesterol profiles. Significantly higher rates of 
abnormal cholesterol levels were found in Indian women. 
 
TABLE 9: Lipid profile* of African and Indian postmenopausal women 
 AFRICAN (n=51) INDIAN (n=55) p value 
 n (%) n (%)  
Cholesterol (mmol/L)  















































*normal values available in appendix C 
 
` 
Table 10 shows the bone mineral density (BMD) profile of both African and Indian 
postmenopausal women attending IALCH. BMD was determined using a dual energy x-ray 
absorptiometry (DEXA) scan. Statistically significant differences were demonstrated between 
African and Indian women with regards to total hip BMD, total hip T score, lumbar spine T 
score and neck of femur BMD. However, there were no statistical differences between 
African and Indian women when looking at the T-scores at the hip, neck of femur and lumbar 
spine. Though the prevalence of osteopaenia and osteoporosis was 55% compared to 35% in 
African women, this did not reach statistical significance (p=0.05). 
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TABLE 10: Bone mineral density* profile of African and Indian postmenopausal 
women 
 AFRICAN (n=51) INDIAN (n=55) p value 
 Mean (SD) Mean (SD)  
Total hip BMD (g/cm2) 0.92 (0.16) -0.46 (1.14) <0.001 
Total hip Tscore 0.83 (0.18) -0.96 (1.37) 0.04 
Lumbar Spine BMD 
(g/cm2) 
0.93 (0.13) 0.88 (0.19) 0.15 
Lumbar Spine Tscore -1.22 (1.27) -1.76 (1.38) 0.04 
Neck of femur BMD 
(g/cm2) 
0.77 (0.13) 0.72 (0.14) 0.03 
Neck of femur Tscore -0.98 (1.04) -1.23 (0.97) 0.19 
 
 
TABLE 11: Bone mineral density profile* of African and Indian postmenopausal 
women  
 AFRICAN (n=51) INDIAN (n=55) p value 
 n (%) n (%)  





































*WHO classification available in appendix C 
† Osteopaenia and Osteoporosis 
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Correlations between cardio-metabolic parameters and bone mineral density (namely total hip 
BMD and lumbar spine BMD) were made. Clinical parameters for the cardio-metabolic 
profile included systolic blood pressure, diastolic blood pressure, height, weight, body mass 
index, waist-hip ratio, stigma of dyslipidaemia and insulin resistance. Biochemical 
parameters included fasting glucose, fasting insulin and fasting lipid values. Scatter plots 
were used to illustrate parametric correlations. 
 
Figure 1: Correlation between BMI and Total hip BMD in African and Indian 
postmenopausal women (n=106) 
 
BMI-total hip BMD (p<0.001) 
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Figure 1 demonstrates a strong positive correlation between BMI and total hip BMD (p < 
0.001). This correlation was stronger in Indian women compared to African women (r
2 
linear= 0.522   vs r
2 
linear = 0.322), illustrated in figure 2 and 3. 
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Figure 4 illustrate a strong positive correlation between BMI and lumbar spine BMD (p < 
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Figure 4: Correlation between BMI and lumbar spine BMD in African and Indian 
postmenopausal women (n=106) 
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Figure 5: Correlation between BMI and lumbar spine BMD in Indian women                                                                           
 
 
Figure 6: Correlation between BMI and lumbar spine BMD in African women 
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There was also a positive correlation between weight and both lumbar spine (p<0.01) and 
total hip BMD (p<0.001), as shown in figures 7 and 10. When African and Indian women 
were analyzed separately (figures 8, 9, 11 and 12), Indian women demonstrated stronger 
correlations between weight and BMD. 
 
Figure 7: Correlation between weight and total hip BMD in African and Indian 
postmenopausal women (n=106) 
 
Weight-total hip BMD (p<0.001) 
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Figure 10: Correlation between weight and lumbar spine BMD in African and Indian 
postmenopausal women (n=106) 
 
Weight-lumbar spine BMD (p<0.001) 
 
Figure 11: Correlation between weight and lumbar spine BMD in African women                                                                                                               
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There were no statistically significant correlations between height and lumbar spine BMD 
(p=0.57) or height and total hip BMD (p=0.95). 
 
A weak correlation was demonstrated between WHR and both lumbar BMD (p=0.06) and 
WHR and total hip BMD (p=0.06). 
 
LDL exhibited a statistically significant inverse correlation to lumbar spine BMD (p=0.03), 
illustrated in figure 13. As LDL values increased, lumbar spine BMD decreased. This 
correlation was comparable amongst African and Indian women as shown in figures 14 and 
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15. A weak correlation was demonstrated between serum LDL cholesterol levels and total hip 
BMD (p=0.07).  
 
There were no statistically significant correlations between serum HDL cholesterol or serum 
triglyceride levels and BMD (lumbar spine or total hip).  
 
 
Figure 13: Correlation between LDL cholesterol and lumbar spine BMD in African and 
Indian postmenopausal women (n=106) 
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Figure 14: Correlation between LDL and lumbar spine BMD in Indian women                                                                            
 
 
Figure 15: Correlation between LDL and lumbar spine BMD in African women                                   
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There were no statistically significant correlations between BMD and SBP or DBP. 
 
Weak correlations were demonstrated between BMD and the clinical stigmata of 
dyslipidaemia or insulin resistance. Weak correlations were also exhibited between BMD 
(both lumbar spine and total hip) and abnormal fasting serum insulin, abnormal fasting serum 

























Menopause is associated with a substantially increased risk of cardiovascular events from 
atherosclerotic vascular disease, regardless of the age of onset of menopause. This may be 
attributed to the changing hormonal milieu which renders women prone to the metabolic 
syndrome. Furthermore, women are susceptible to risk factors like a history of polycystic 
ovarian syndrome and pre-eclampsia which, when present, doubles the background risk of 
CVD (International Menopause Society Concensus Statement: Aging, menopause, 
cardiovascular disease and HRT; 2009).
  
 
Additionally, osteoporosis affects one-third of postmenopausal women, resulting in 
significant morbidity, mortality and cost (Hough et al., 2010).  
 
Historically cardiovascular disease and osteoporosis were considered unrelated. However, in 
the last decade, studies by Marcovitz et al
 
(2005) and Varma et al (2008) have suggested that 
osteoporosis could be used as an independent predictor of coronary artery disease in women. 
 
. 
With this in mind, an understanding of the cardio-metabolic profile, and similarly an 
awareness of the high prevalence of low bone mineral density, is pivotal for the identification 
of patients at risk for a cardiovascular event and fracture. 
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In this study there was a high prevalence of climacteric symptoms amongst African and 
Indian women. This finding may be a feature of a tertiary set-up where symptomatology is 
elicited and treatment offered. A significantly higher proportion of Indian women (50.9%) on 
HRT preparations when compared to African women (23.5%). This may be attributed to 
more Indian women reporting, and requesting, treatment for their troublesome 
symptomatology. 
 
There was a high prevalence of hypertension, diabetes, hypercholesterolemia, ischaemic heart 
disease and low bone mineral density amongst both African and Indian women in the study. 
Historically, this was not a common finding amongst African postmenopausal women. Our 
findings could represent a shift towards urbanisation amongst African ethnicities, with 
environmental factors like diet and lifestyle negatively impacting on cardio-metabolic 
parameters. Furthermore, one would expect a high risk profile of patients at a study site like 
our tertiary institution.  
 
The majority of women attending our clinic were hypertensive. More than 50% of Indian 
women and almost 30% of African women were diabetic, over 30% of Indian women and 
20% of African women demonstrated dyslipidaemia and the prevalence of ischaemic heart 
disease was low overall. The study thus demonstrated that there was a higher prevalence of 
the markers of cardiovascular disease in both ethnic groups, however the risk was greater in 
Indian postmenopausal women as compared to African postmenopausal women. This finding 
may be associated with a genetic predisposition for cardiovascular disease amongst Indian 
women.  
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There were no statistical differences amongst the African and Indian women regarding diet, 
lifestyle, smoking and alcohol intake. This finding may be attributed to the widespread 
urbanization amongst all South African ethnicities (Kruger et al., 2011).  
In our clinic, the uptake of various menopausal therapies was evaluated. Many women used 
HRT and calcium supplementation during the menopause. Of significance, was that half of 
all Indian women and only a quarter of African women were on hormone replacement 
therapy. However, for calcium use, the converse was true – over 50% of African women and 
only 23% on Indian women were on calcium. Furthermore, significantly more Indian women 
were on an antiresorptive agent compared to African women. The uptake of Vitamin D 
supplements or alternatives to HRT was low in both African and Indian women. We 
anticipated that a large proportion of women in our study would be on some form of 
treatment or supplementation in view of the study site being of a tertiary, high risk nature. 
The use of antiresorptive agents was significantly higher among Indian postmenopausal 
women. Most women used Alendronate, a bisphosphonate. There were very few patients on 
Strontium Ranelate. These findings may confirm the higher prevalence of osteoporosis 
among Indian women, necessitating treatment with antiresorptives rather than 
supplementation. 
 
The majority (82%) of African and Indian women had a BMI greater than 25. This finding 
seems to be in line with WHO global estimates of an increasing prevalence of obesity in 
developing countries, especially amongst women. African women, however, had a 
significantly greater weight and BMI than Indian women, with 68% of African women 
having a BMI > 30. Despite an expected link between increased BMI and impaired cardio-
metabolic parameters, the frequency of hypertension was similar amongst African and Indian 
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women. Both African and Indian women demonstrated a high prevalence of abnormal fasting 
glucose levels and abnormal fasting insulin. This finding may represent the nutritional, 
demographic, epidemiological, and socioeconomic transitions occurring in developing 
countries, resulting in shifts in dietary and physical activity patterns and a change in ethnic-
specific cardio-metabolic profiles.  
 
In our study, abnormal lipid profiles were demonstrated in the majority of postmenopausal 
women, with Indian women showing greater derangements in cholesterol, triglyceride, HDL 
and LDL values.                                                                                                                     
Prior studies also showed this association. Mulukutla et al (2008) investigated the 
relationship between race and atherogenic dyslipidaemia. The study was performed on North 
American Caucasian and Black postmenopausal women, as well as Indian postmenopausal 
women from Chennai, India. He found that the prevalence of LDL and TG/HDL ratio >3 was 
greatest among Asian Indians and smallest among Africans. Genetic predisposition and 
characteristic body composition were seen as important contributors to dyslipidaemia and 
atherosclerosis in Indian women specifically (Misra et al., 2004).                                                                                               
 
In our study, Indian women demonstrated a higher prevalence of the markers of metabolic 
syndrome, and thus cardiovascular disease, despite having a lower incidence of obesity. 
Although a gradient relationship exists between obesity and the probability of metabolic 
syndrome, not all obese women have metabolic syndrome and not all women with metabolic 
syndrome are obese. Ruderman et al (1998) classifies Asian women as ‘metabolically obese’, 
with several metabolic derangements but are non-obese by conventional BMI standards. 
Despite a normal BMI, Indian women demonstrate a high body fat, abdominal adiposity and 
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thick truncal subcutaneous fat which individually, or in combination, contribute to insulin 
resistance, dyslipidaemia and hyperglycaemia demonstrated in the study. Thus visceral 
adiposity and body fat distribution correlates better with a higher prevalence of metabolic 
syndrome and increased cardiovascular risk than BMI. Visceral obesity in both ethnic groups 
was not measured in this study however, based on previous literature, it’s presence, 
irrespective of BMI,  may explain our results regarding the biochemical and lipid profiles in 
Indian women. It seems likely that underlying adiposity, a predictor of metabolic syndrome, 
might be misclassified using BMI in the literature. With this in mind, consideration should be 
given to lowering BMI cut-offs for diagnosis of overweight and obesity in Indian women  as 
opposed to current guidelines. 
 
Bone mineral density analysis demonstrated a higher prevalence of both osteopaenia and 
osteoporosis among Indian postmenopausal women as compared to African postmenopausal 
women - at the hip, spine and neck of femur. This finding could be related to ethnic 
differences in the genetic make-up. Sigurdsson et al (2008) assessed the impact of genetics on 
bone mineral density in North American Caucasian, African-American and Hispanic 
postmenopausal women. The study demonstrated that genetics among different ethnicities 
were more important than environmental factors in the pathogenesis of low bone mineral 
density. Mitchell et al (2011) implicated nuclear factor κB and specific genes involved in the 
oestrogen endocrine pathways in the pathogenesis of osteopaenia and osteoporosis. In a 
North American study examining the effect of genetics on bone mineral density in the 
African population, Sudanese immigrants were compared to the Caucasian and Asian 
populations (Gong et al., 2006). The study found that 18 polymorphisms in 13 genes were 
associated with bone mineral density and 17 were significantly different in allele between the 
Sudanese population and Caucasians or Asians.  
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In addition, the favourable bone density reported in African women may be attributed to 
more African women taking calcium supplementation.  Another explanation could be the 
relationship between BMI, ethnicity and BMD - increased BMI (specifically lean body mass) 
is associated with increased mechanical loading and thus plays an integral role in improved 
bone mass. Finkelstein et al (2008) demonstrated that body weight was a major determinant 
of the rate of menopausal BMD loss. Barret-Connor et al (2005) showed that body weight 
was influenced by ethnicity, with the highest BMD being reported in Black women.  Recent 
literature favours the assumption that ethnicity and body weight are strong determinants of 
baseline bone density and influence the rate of bone mineral loss and fracture risk, which  
may be reflected by a difference in the rate of bone loss, a difference in the peak bone mass 
or both. (Finkelstein et al., 2002; Finkelstein et al., 2008; Zhao et al., 2007; Kadam et al., 
2010)  
  
This study found a strong positive correlation between body mass index and both lumbar 
spine and total hip bone mineral density (p < 0.01). There was also a positive correlation 
between weight and both lumbar spine and total hip bone mineral density (p<0.01).  
 
Tsuda et al (2001) examined the bone mineral density in elderly Japanese women. The study 
found an inversely proportional relationship between systolic blood pressure and bone 
mineral density, with no correlation between diastolic blood pressure and BMD. In our study, 
there were no significant correlations between waist-hip ratio and bone mineral density or 
blood pressure and bone mineral density.  
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Furthermore, no correlations were exhibited between bone mineral density (both lumbar 
spine and total hip) and an abnormal fasting serum glucose; abnormal fasting insulin, 
abnormal serum thyroxine or the clinical stigmata of dyslipidaemia or insulin resistance. 
In our study we found no correlation between social habits, which included alcohol 
consumption and smoking, and BMD. This finding could be the result of the small number of 
women who consumed alcohol or smoked in our study.  
 
However, the relationship between social habits and BMD has been explored in earlier 
studies. Ganry et al (2000) and Ilich et al (2002) found higher bone densities in 
postmenopausal women that consumed moderate quantities of alcohol. These studies 
postulated that alcohol increases endogenous oestrogen which has beneficial effects on bone. 
 
Ganry et al (2000) examined the association between alcohol consumption and bone mineral 
density in French women aged 75 years or older. Alcohol intake was determined by a self-
administered questionnaire and bone mineral density was measured at the proximal femur 
using dual-photon X-ray absorptiometry. Their study suggested that moderate drinking (e.g., 
1-3 glasses of wine per day) is associated with an increase in trochanteric bone mineral 
density in elderly ambulatory women. However, the study reported detrimental effects on 
bone mass with higher alcohol intake.  
 
Further to the study by Ganry et al (2000), Illich et al (2002) performed a small cross-
sectional study on Caucasian women in North America. Postmenopausal women were 
reported as healthy and free of medications affecting bones. Alcohol consumption was 
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assessed by questionnaires determining frequency and amount. Bone mineral density of 
multiple skeletal regions and body composition were measured by dual X-ray absorptiometry. 
The study demonstrated that consumption of small/moderate amounts of alcohol was 
associated with improved bone mineral density. 
 
Egger et al (1996) and Ilich et al (2002) examined the relationship between smoking and 
bone mineral density. Egger et al (1996) performed a cross-sectional study in the United 
Kingdom (East Hertfordshire) on postmenopausal women between the ages of 61 and 73 
years.  The study found that current smokers have a BMD value that was 7.7% lower than in 
women who had never smoked. They hypothesized that this may be due to the vaso-spastic 
effect of nicotine on blood vessel walls resulting in bone death and impaired mineral density. 
Illich et al (2002) explored the relationship between smoking and bone mineral density on 
North American Caucasian women (average age 61 years). A self-administered questionnaire 
determined a history of smoking, including number of years and packages smoked/day. The 
study demonstrated that past smoking was associated with bone loss in most skeletal sites. 
 
A current survey of the literature demonstrates no consensus regarding the relationship 
between lipid profile and bone mineral density - while studies show that a pro-atherogenic 
profile is associated with a higher bone mineral density (Makovey et al., 2009; D’Amelio et 
al., 2008),
 
others demonstrate that the rate of bone loss is positively related to cardiovascular 
events (Bagger et al., 2007). 
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Our study demonstrated a statistically significant inverse relationship between serum LDL 
cholesterol levels and lumbar spine bone mineral density (p=0.03). These findings were 
similar to previous studies by Makovey et al (2009) and Yamaguchi et al (2002). There was 
no statistically significant correlation between cholesterol, HDL cholesterol or triglycerides 
and bone mineral density in this study. It is possible that our small sample size did not elicit a 
difference, however a larger study may be able to reproduce results similar to previous larger 
studies. 
 
Makovey et al (2009) examined the influence of age, menopausal status and hormone 
replacement therapy (HRT) on the relationship between serum cholesterol and BMD in 273 
postmenopausal women in Australia. The study demonstrated a modest inverse relationship 
between body bone mineral density (lumbar spine and whole body) and serum total 
cholesterol. 
 
In a cross-sectional study of 173 Italian women in menopause, D’Amelio et al (2008) 
demonstrated that HDL was significantly higher in osteoporotic patients than in controls and 
the risk of osteoporosis was significantly higher in women with higher level of HDL. The 
study concluded that a pro-atherogenic lipid profile is associated with higher bone mineral 
density. 
 
An observational study by Bagger et al (2007) on 1176 Danish postmenopausal women 
examined the relationship between serum lipids and bone mineral density (Bagger et al., 
2007).  The study demonstrated that serum lipids are indirect modulators of bone mineral 
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density via promotion of atherosclerosis, which affects bone metabolism locally, especially 
when skeletal sites are supplied by end-arteries. 
Yamaguchi et al (2002) evaluated the relationships between plasma lipids (total cholesterol, 
LDL, HDL, and triglycerides) and bone mineral density (lumbar spine, femoral neck, radius 
or total body) as well as the presence of vertebral fractures in 214 Japanese postmenopausal 
women with a mean age of 62.7 years. Their study showed that plasma LDL and HDL levels 
were inversely and positively correlated with both bone mineral density values at the radius 
and lumbar spine, respectively, while low plasma triglyceride levels were associated with the 
presence of vertebral fractures in postmenopausal women. The study concluded that plasma 
lipids are related to bone mass and bone fragility, and might be the common factor underlying 
both osteoporosis and atherosclerosis. 
 
The findings of our study suggest that South African postmenopausal Indian and African 
women have similar presentations and profiles to women globally.  
The limitations of this study were that it included patients from a tertiary institute that were 
‘high risk’ by definition. These patients may have a multitude of chronic conditions, 
necessitating management at a tertiary hospital. Thus, this patient profile may not be 
applicable to the general postmenopausal population. The high rates of osteoporosis and 
cardiovascular disease in the population at large complicate investigations of causality. 
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The true prevalence of low bone mineral density may be skewed by the use of 
bisphosphonates and other treatments for osteoporosis. Similarly, the true value of specific 
biochemical investigations may have been altered or masked by specific medications 
(namely, insulin values in patients on oral hypoglycaemic agents). There are a large number 
of shared confounders in the study (namely age, smoking, exercise, drug use). These 
confounders may complicate investigations determining the association and causal link.  
 
Although there were small numbers of African and Indian women in the sample population, 
we found a high prevalence of cardiovascular risk factors and low BMD amongst the local 
menopausal population attending a tertiary referral or high risk clinic, irrespective of 
ethnicity. BMI and weight showed a positive correlation with bone mineral density and an 
increasing LDL value was negatively correlated with bone mineral density. It thus becomes 
necessary that a screening lipid profile during the peri-menopausal years, coupled with early 
and appropriate lifestyle management regarding body mass index/ weight may limit the 
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CHAPTER 5 
CONCLUSION AND RECOMMENDATIONS 
 
Coronary artery disease and low bone mineral density are common conditions in the aging 
population.  
 
Cardiovascular risk is increased in the menopause transition making it one of the leading 
causes of mortality amongst these women. 
Furthermore, statistics from the National Osteoporosis Foundation of South Africa have 
shown that osteoporosis affects one third of South African women above the age of 50 years, 
with a high prevalence of fracture-related morbidity and mortality. This makes osteoporosis, 
and osteoporotic fractures, one of the major public health problems to date.  
 
Many postmenopausal women appear healthy, with no clinical features of cardiovascular 
disease or low bone density. However, our results demonstrated a high prevalence of 
cardiovascular risk factors and low bone mineral density in postmenopausal women, 
irrespective of ethnicity. Underlying adiposity, and not BMI, should be a predictor of 
metabolic syndrome.   
 
Contemporary management of these women should include a thorough assessment of their 
global cardiovascular and fracture risk during the peri-menopausal years. Relevant 
biochemical investigations and bone density assessment should be followed by goal-directed 
holistic management based on the individual’s risk profile. There should be judicious follow 
up to ensure the initiation of treatment, were necessary. 
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Locally, there are no clear guidelines for the screening and assessment of cardiovascular 
disease and low bone mineral density in the menopause. We therefore recommend the 
development of screening and treatment protocols locally to assist in risk stratification and 




















Ahlborg HG, Johnell O, Nilsson BE et al. Bone loss in relation to menopause: a prospective 
study during 16 years. Bone 2001; 28: 327-331 
 
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—new world-wide definition. A 
consensus statement from the International Diabetes Federation. Diabetes Med. 2006; 23: 
469–480 
 
American Heart Association, Women and cardiovascular disease facts, American Heart 
Association, 2007 
 
Aminoff MJ, Greenberg DA, Simon RP. Clinical Neurology (6th ed.). Lange: McGraw-
Hill Medical. 2005. p241–5 
 
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in 
postmenopausal women with hysterectomy: the Women's Health Initiative randomized 
controlled trial. JAMA. 2004; 291(14): 1701-12 
 
Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of 
follow-up at 8 years. Eur Heart J. Feb 1998; 19 Suppl A: A2-11 
 
Atsma F, Bartelink ML, Grobbee DE et al. Postmenopausal status and early menopause 
as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006; 
13: 265-79 
 
- 85 - 
 
Bagger YZ, Tankó LB, Alexandersen P, Qin G, Christiansen C; Prospective 
Epidemiological Risk Factors Study Group. Radiographic measure of aorta calcification 
is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med. 2006 
Jun; 259(6):598-605 
 
Baldini V, Mastropasqua M, Francucci CM et al. Cardiovascular disease and 
osteoporosis. 
 
J Endocrinol Invest. 2005; 28(10 Suppl): 69-72. 
 
Bansal D, McGregor R. Calcium regulated secretion of tissue plasminogen activator and 
parathyroid hormone for human parathyroid cells. J Clin Endocrin Metab  1992; 74: 266-
271 
 
BarengoltsEI, Berman M, Kukreja SC et al. Osteoporosis and atherosclerosis in 
asymptomatic postmenopausal women. Calcif Tissue Int. 1998; 62: 209-213 
 
 
Baron YM, Galea R, Brincat M. Carotid artery wall changes in estrogen treated and 
untreated postmenopausal women. Obstet Gynecol. 1998; 91: 982-986 
 
 
 Barret-Connor E, Siris E, Wehren L. Ethnic diff in BMD Osteoporosis and Fracture Risk 




Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular 
events and breast cancer in postmenopausal women. N Engl J Med 2006; 355(2): 125–37 
- 86 - 
 
 
Board of the International Menopause Society, Pines A, Sturdee DW et al. IMS updated 
recommendations on postmenopausal hormone therapy. Climacteric. 2007; 10: 181–194 
 
British Menopause Society Council Consensus Statement. Alternative and 
complementary therapies.                                                                                                 
 
Brown TT. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a 
meta-analytic review. AIDS 2006; 20(17): 2165-74 
 
Browner WS, Pressman AR et al. Association between low bone mineral density and 
stroke in elderly women: the study of osteoporotic fractures. Stroke 1993; 24: 940-946 
 
Burger HG, Robertson DM et al. Serum inhibins A and B fall differently as FSH rises in 
the perimenopausal women. Clin Endocrinol. 1998; 48: 809-813 
 
Busch CM, Zonderman AB, Costa PT Jnr. Menopausal transition and psychological 
distress in a nationally representative sample: is menopause associated with psychological 
distress? J Aging Health. 1994; 6: 209  
 
Carr M.C. The Emergence of the Metabolic Syndrome with Menopause. The Journal of 
Clinical Endocrinology & Metabolism.2003; 88 (6): 2404-2411 
 
 
Cadarette SM, Jaglal SB, Kreiger N et al. Development and validation of the 
Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone 
densitometry. CMAJ. 2000; 162: 1289–1294 
 
- 87 - 
 
Calleja-Aguis J, Brincat MP. Effects of hormone replacement therapy on connective 
tissue: why is this important? Best Practice and Research Clinical Obstetrics and 
Gynaecology. 2009; 23: 121-127 
 
Campbell AJ, Robertson MC, Gardner MM et al. Psychotrophic medication withdrawal 
and a home-based exercise programme to prevent falls: a randomized controlled trial. J 
AM Geriatr Soc. 1994; 47: 850-853 
 
Chattopadhyay N, Quinn SJ, Kifor O et al. The calcium-sensing receptor (CaR) is 
involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol. 
2007; 74: 438–447 
 
Colon-Emeric C. Ten vs. five years of bisphosphonate treatment for osteoporosis. JAMA. 
2006; 296: 2968–2969 
 
Conroy RM et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: 
the SCORE project. Eur Heart J 2003; 24: 987-1003 
 
D’Amelio P, Di Bella S, Tamone C et al HDL cholesterol and bone mineral density in 
normal weight postmenopausal women: is there a possible association? Panminerva Med 
2008; 50(2): 89-96 
 
 
Dawson Hughes B, Heaney RP, Holick MF et al. Estimates of optimal vitamin D status. 
Osteoporos Int. 2005; 16: 713–716 
 
- 88 - 
 
De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C et al. Third Joint Task Force of 
European, Other Societies on Cardiovascular Disease Prevention in Clinical Practice. 
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint 
Task Force of European and Other Societies on Cardiovascular Disease Prevention in 
Clinical Practice. Eur Heart Journal.  2003; 24:1601–1610 
 
De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a 
meta-analysis. Osteoporosis International. 2005;16:1330-1338 
 
DE Morales , A Kelly, B Mcgowen et al. Estrogen Promotes Angiogenic Activity in 
Human Umbilical Vein Endothelial Cells In Vitro and in a Murine Model. 
Circulation.1995; 91: 755-763 
 
De Villiers TJ. Bone health and osteoporosis in postmenopausal women. Best Practise and 
Research Clinical Obstetrics and Gynaecology 2009; 23: 73-85 
 
Egger P, Duggleby S, Hobbs R et al. Cigarette smoking and bone mineral density in the 
elderly. Epidemiol Community Health. 1996; 50: 47-50   
 
 
Epstein FH. The protective effects of oestrogen on the cardiovascular system. NEJM 
1999; 23: 1801-1810 
 
Eriksson M, Egberg N, Wamala S, et al. Relationship between plasma fibrinogen and 
coronary heart disease in women. Arterioscler Thromb Vasc Biol. Jan 1999; 19(1): 67-72 
- 89 - 
 
Espallargues M et al. Identifying bone-mass-related risk factors for fracture to guide bone 
densitometry measurements: a systematic review of the literature. Osteoporosis 
International.  2001; 12: 811–822 
 
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in 
postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year 
randomized clinical trial. JAMA. 1999; 282(7): 637–45 
 
 
Felson D, Zang Y, hannan M et al. Alcohol Intake and Bone Mineral Density in Elderly 
Men and Women. The Framingham Study. Am. J. Epidemiol. 1995; 142 (5):485-492 
 
 
Finkelstein J, Brockwell S et al  Bone mineral density changes during the menopause 
transition in a multiethnic cohort of women. Journal Clin Endocrinol Metab. 2008; 93: 
861-868 
 
Finkelstein JS, Lee MT, Sowers M et al. Ethnic Variation in Bone Density in 
Premenopausal and Early Perimenopausal Women: Effects of Anthropometric and 
Lifestyle Factors. J Clin Endocrinol Metab. 2002; 87: 3057-3067 
 
Fiore CE, Pennisi P, Pulvirenti I. Bisphosphonates and atherosclerosis. J Endocrinol 
Invest. 2009; 32 (Suppl 4): 38-43   
 
Fujimaki T, Kurabayashi T, Yamamoto Y et al. Effects of progesterone of the metabolism 
of cancellous bone in young oopherectomised rats. J Obstet Gynecol.1995; 21: 31-36 
 
- 90 - 
 
Ganry O, Baudoin C, Fardellone P.  Effect of Alcohol Intake on bone Mineral 
Density in Elderly Women. The EPIDOS Study. Am J Epidemiol. 2000; 151: 773–80 
 
 
George LK, Weiler SJ. Sexuality in middle life.  Arch Gen Psychiatr. 1981; 39: 9191 
 
Ghorayeb I, Bioulac B, Scribans c et al. Perceived severity of restless leg syndrome 
across the female life cycle. Sleep Med. 2007 
 
Godstein F, Manson JE, Colditz GA et al. A prospective observational study of 
postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann 
Intern Med. 2000; 133: 933-941 
 
Gong G, Haynatzki G, Haynatzka V. Bone Mineral Density-Affecting Genes in Africans. 
Journal of National Medical Association. 2006; 98(7): 1102-1108 
 
Gorodeski G. Update on cardiovascular disease in women. Best Practices and research 
Clinical Obstetrics and Gynaecology. 2002; 16: 329-355 
 
Grady D, Applegate W, Bush T, et al. Heart and Estrogen/progestin Replacement Study 
(HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998; 19(4): 
314-35.  
 
Grady D, Herrington D, Bittner V, and Heart and Estrogen/progestin Replacement Study 
Follow-up (HERS II). Cardiovascular disease outcomes during 6·8 years of hormone 
therapy. JAMA 2002; 288: 49–57 
- 91 - 
 
Harvey P. Oestrogen and vascular : The heart and blood vessels in health and disease 
supplement . Australian and New Zealand Journal of Medicine. 1999; 29(3): 473-479 
 
Hodis HN, Mack WJ. Postmenopausal hormone therapy in clinical perspective. 
Menopause. 2007; 14: 944-957 
 
Hoekman K, Lowik C, van der Ruit M et al. Regulation of the production of plasminogen 
activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-
like cells. Bone Miner. 1991; 14: 189-204 
 
http;//www.shef.ac.uk/FRAX/ site last visited 21/12/2010 
 
Hough S, Ascott-Evans BH, Browns L et al. NOFSA guidelines for the diagnosis and 
management of Osteoporosis. 2010 
 
Hough FS. Position paper of the National Osteoporosis Foundation of South Africa on the 
use of parathyroidhormone (PTH 1-34) in the treatment of osteoporosis. S Afr Med J. 
2004; 94: 175–177 
 
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for 
secondary prevention of coronary heart disease in postmenopausal women. Heart and 
Estrogen/progestin Replacement Study (HERS) Research Group. JAMA.  1998; 280(7): 
605-13 
 
Hyun A.P, Jung S. Lee, Lewis H.K et al. The Journal of Clinical Endocrinology & 
Metabolism. 1992; 10: 3809–3815 
- 92 - 
 
Ilich J, Brownbill R, Tamborini L et al. To Drink or Not to Drink: How Are Alcohol, 
Caffeine and Past Smoking Related to Bone Mineral Density in Elderly Women? J Am 
Coll Nutr. 2002; 21: 536-544 
 
 Institute of medicine of the national academies. Press release.11/30/2010 
 
Jackson RD, Wactawski-Wende J, LaCroix AZ et al. Effects of conjugated equine 
estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: 
results from the women’s health initiative randomized trial. J Bone Miner Res. 2006; 21: 
817–828 
 
Jenkins MR & Denison AV. Smoking status as a predictor of hip fracture risk in 
postmenopausal women of northwest Texas. Prev Chronic Dis. 2008; 5: A09 
 
Jorgensen L, Engstad T et al. Bone mineral density in acute stroke patients: low bone 
mineral density may predict first stroke in women. Stroke 2001;32:47-51 
 
Kadam N, Chiplonkar S, Khadilkar A et al. Low bone mass in urban Indian women above 
40 years of age: the prevalence of risk factors. Gynecol Endocrinol. 2010; 26(12): 909-
917 
 
Kanis JA, Johansson H, Johnell O et al. Alcohol intake as a risk factor for fracture. 
Osteoporos Int. 2005; 16: 737–742 
 
Krassas G.E and Papadopoulou P. Oestrogen action on bone cells.  J Musculoskel Neuron 
Interact.2001; 2(2): 143-151 
- 93 - 
 
Kruger M.C, Kruger I.M, Wentzel-Viljoen E et al. Urbanization of black South African 
women may increase risk of low bone mass due to low vitamin D status, low calcium 
intake, and high bone turnover. Nutr Res. 2011; 31(10):748-58 
 
 
La Marca A, Guilini S, Malmusi S  et al. Anti-mullerian hormone concentrations in 
maternal serum during pregnancy. Hum Reprod. 2005; 20: 1569-1572 
 
 
Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 
2006; 194: S3–S11 
 
 
Lanham-New SA. The balance of bone health: tipping the scales in favor of potassium-
rich, bicarbonate-rich foods. J Nutr. 2008; 138: 172S–177S 
 
Lewiecki EM, Watts NB, McClung MR, et al. Position statement. Official positions of the 
International Society for Clinical Densitometry. J Clin Endocrinol Metab. 2004; 89: 
3651–3655 
 
Liang M, Liao EY, Xu X et al. Effects of progesterone and 18-methyl levonorgesterel on 
osteoblastic cells. Endocr Res. 2003; 29: 483-501 
 
Liang YL, Teede H, Shiel LM et al. Effects of oestrogen and progesterone on age-related 
arterial change of postmenopausal women. Clin Exp Pharmacol Physiol. 1997; 24: 457-
459 
 
- 94 - 
 
Maclean C, Newberry S, Maglione M et al. Comparative effectiveness of treatments to 
prevent fractures in men and women with low bone density or osteoporosis. Ann Intern 
Med. 2008; 148: 197–213 
 
MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for 
hot flushes: a systematic review. Climateric. 2001; 4: 58-74 
 
Madge R Vickers,Alastair H MacLennan,Beverley Lawton. Main morbidities recorded in 
the women’s international study of long duration oestrogen after menopause (WISDOM): 
a randomised controlled trial of hormone replacement therapy in postmenopausal women. 
BMJ. 2007; 33: 239-244 
 
Maillard C, Berruyer M et al. Protein S, a Vitamin K dependant protein, is a bone matrix 




 Makovey J, Chen JS, Hayward C et al Association between serum cholesterol and bone 
mineral density Bone 2008; 44: 208–213   
   
Management of osteoporosis in postmenopausal women: Position statement of the North 
American Menopause Society. Menopause. 2010; 17 (1): 25-54 
 
- 95 - 
 
Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery 
calcification. N Engl J Med. 2007; 356(25): 2591-602  
 
 Marcovitz PA, Tran HH et al. Usefulness of bone mineral density to predict significant 
coronary artery disease. Am J Cardiol 2005; 96: 1059-1063 
 
Matthews K, Abrams B, Crawford S et al. "Body mass index in mid-life women: relative 
influence of menopause, hormone use, and ethnicity".   Journal of the International 
Association for the Study of Obesity. 2001; 25: 6 
 
 
Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. The 
American Journal of Cardiology.2002; 89 (12): Pages 12-1 
 
Mendelsohn ME, Kara RE. Mechanisms of disease. NEJM. 1999; 340(23): 1801-1810 
 
Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of 




Michaëlsson K, Bergström B, Mallmin M et al. Screening for osteopenia and 




- 96 - 
 
Miro F, Parker SW, Aspinall LJ et al. Origins and consequences of the elongation of the 
human menstrual cycle during the menopause transition: the FREEDOM study. J 
Endocrin Metab. 2004; 89: 4910-4915 
 
Misra A, Khuran A. Obesity and the Metabolic Syndrome in Developing Countries. 
Journal of Clinical Endocrinology & Metabolism. 2008; 93: No. 11 Supplement 1 s9-s3 
 
  
Misra A, Luthra K, Vikram NK et al. Dyslipidemia in Asian Indians : Determinants and 
Significance. JAPI. 2004; 52: 137-142 
 
 
Mitchell B and Yerges-Armstrong L. The Genetics of Bone Loss: Challenges and 
Prospects. The Journal of Clinical Endocrinology & Metabolism. 2011; 94: 2010-2865 
 
Mosca L, Banka CL, Benjamin EJ et al. Evidence based guidelines for cardiovascular 
disease prevention in women: 2007 update. Circulation 2007; 115: 1482 
 
Mulukutla SR, Venkitachalam L, Marroquin OC et al.  Population variations in 
atherogenic dyslipidemia: A report from the HeartSCORE and IndiaSCORE Studies. 
Journal of Clinical Lipidology. 2008; 2: 410-417 
 
 
National Center for Complementary and Alternative Medicine. Menopausal Symptoms 
and CAM. Available from: http://nccam.nih.gov/health/menopauseandcam/ 
 
 
- 97 - 
 
National Osteoporosis Foundation. America’s Bone Health: The State of Osteoporosis 




National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of 
Osteoporosis.Washington, DC: National Osteoporosis Foundation; 2003 
 
 
Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on 
fractures and bone mineral density in post menopausal women with osteoporosis. N Engl J 
Med. 2001; 344: 1434–1441. 
 
Ness J, Aronow WS. Comparison of prevalence of atherosclerotic vascular disease in 
postmenopausal women with osteoporosis or osteopaenia versus without osteoporosis or 
osteopaenia. Am J Cardiol 2006; 97: 1427-1428         
 
Ohta H, Makita K, Suda Y et al. Influence of oophorectomy on serum levels of sex 
steroids and bone metabolism and assessment of bone mineral density in lumbar 
trabeculae bone by QCT-C value.  J Bone Miner Res. 1992; 7: 659-665 
 
Perrien D, Achenbach SJ, Bledsoe SE et al. Bone Turnover across the Menopause 
Transition: Correlations with Inhibins and Follicle-Stimulating Hormone. The Journal of 
Clinical Endocrinology & Metabolism. 2006; 91(5): 1848-1854 
 
Rajzbaum G, Bezie Y. Review: Postmenopausal osteoporosis and atheroma. Joint Bone 
Spine. 2006; 73: 661-666 
 
- 98 - 
 
Royal College and Obstetricians and Gynaecologists. Alternatives to HRT for the 
Management of Symptoms of the Menopause. Scientific Advisory Committee Opinion 
Paper 6. London: RCOG, 2006. Available from: www.rcog.org.uk 
 
Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of        
nonvertebral fractures in postmenopausal women with osteoporosis: treatment of 




Richmond B. DXA scanning to diagnose osteoporosis: Do you know what the results 
mean? The Cleveland Journal of Clinical Medicine. International Society for Clinical 
Densitometry  2003; 70(4): 353-359 
 
Ruderman N, Chisholm D, Pi-Sunyer X et al. The metabolically obese, normal-weight 
individual revisited. Diabetes. 1998; 47:699–713 
 
Rymer J, Morris EP. Extracts from clinical evidence. Menopausal symptoms. BMJ 2000; 
321: 1516-1519 
 
Sator MO, Joura EA, Gruber DM et al. The effect of hormone replacement therapy on 
carotid arteries: measurement with a high frequency ultrasound system. Maturitas 1998; 
30: 63-68 
 
Sennerby U, Melhus H, Gedeborg R et al. Cardiovascular Diseases and Risk of Hip 
Fracture. JAMA 2009; 302(15): 1666-1673 
 
- 99 - 
 
Sigurdsson G,  Halldorsson B, Styrkarsdotti U et al. Impact of Genetics on Low Bone 
Mass in Adults. Journal of Bone and Mineral Research. 2008; 23: 1584–1590 
Siris ES, Chen YT, Abbott TA et al. Bone mineral density thresholds for pharmacological 
intervention to prevent fractures. Arch Intern Med. 2004; 164: 1108–1112 
Song Y, Manson J, Meigs J et al. Comparison of usefulness of Body Mass Index versus 
metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J 
Cardiol. 2007; 100(11): 1654–1658 
Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7
th
 ed. 
Lippincott, Williams and Wilkins, 2005 
 
Stevenson JC, Crook D, Godsland IF. Insulin resistance: syndrome or tendancy? Lancet. 
1995; 346: 100-103 
 
Sturdee D.W, Collins P, Genazzani A.R. International Menopause Society Consensus 
Statement Aging, menopause, cardiovascular disease and HRT. Aging, menopause, 
cardiovascular disease and HRT. 8th International Menopause Society Workshop. 
Climacteric. 2009; 12: 368–377 
 
T. Johannes de Villiers. Bone health and osteoporosis in postmenopausal women. Best 
Practice & Research Clinical Obstetrics and Gynaecology. 2009; 23: 73–85 
 
Tang BMP, Eslick GD, Nowson C et al. Use of calcium or calcium in combination with 
vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and 
older: a meta-analysis. Lancet. 2007; 370: 657–666 
 
- 100 - 
 
Tanko LB, Bagger YZ et al. Is cholesterol or BMD a better predictor of later cardiovascular 
disease in women? World congress of osteoporosis, Lisbon, Portugal 2002. Osteoporosis 
International.  2002; 13 (supplement 1): s68-s69 
 
Tankó LB, Christiansen C, Cox DA et al. Relationship between osteoporosis and 
cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005  ;20(11): 1912-
20 
 
The Writing Group for the ISCD Position Development Conference. Position statement: 
Executive summary. J Clin Densitometry. 2004; 7: 7–12 
 
Tremollieres FA, Cigagna F, Alquier C et al. Effect of hormone replacement therapy on 
age-related increase in carotid artery intima-media thickness in postmenopausal women. 
Atherosclerosis. 2000; 153: 81-88 
 
 Tsuda K, Nishio I et al. Bone mineral density in women with essential hypertention. Am 
J Hypertension 2001; 14: 704-707 
 
Uzzan B, Cohen R et al Effects of statins on bone mineral density: a meta-analysis of 
clinical studies. Bone 2007; 40: 1581-1587 
 
van der Klift M, de Laet CD, Pols HA. Assessment of fracture risk: Who should be 
treated for osteoporosis? Best Pract Res Clin Rheumatol. 2005; 19: 937–950 
 
Varma R, Aronow WS et al. Relation of bone mineral density to frequency of coronary 
heart disease. Am J Cardiol 2008; 101: 1103-1104 
 
- 101 - 
 
Vincent KR, Braith RW. Resistance exercise and bone turnover in elderly men and 
women. Med. Sci. Sports Exerc. 2002; 34: 17-23  
 
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of 
estrogen-replacement therapy after ischemic stroke. N Engl J Med.  2001; 345: 1243–49 
 
 
Von der Recke P, Hansen MA et al. The association between low bone mass at the 




Wagner JD, Clarkson TB. The applicability of hormonal effects on atherosclerosis in 
animals to heart disease in postmenopausal women. Semin Reprod Med.  2005; 23(2): 
149-56.  
 
Walton C, Godsland IF, Proudler AJ et al. The effect of the menopause on insulin 
sensitivity, secretion and elimination in non-obese healthy women. Eur J Clin Invest. 
1993; 23: 466-473 
 
Weinstein L, Ullery B. Identification of at-risk women for osteoporosis screening. Am J 
Obstet Gynecol. 2000; 183: 547–549 
World Health Organization. Controlling the global obesity epidemic. Available at: 
http://www.who.int/nutrition/topics/obesity/en/index.html.  
 
World Health Organisation. Research on the menopause in the 1990’s. Report of a WHO 
Scientific Group. Geneva: WHO, 1998 
 
- 102 - 
 
World Health Organization. Prevention and management of osteoporosis. WHO 
Technical Report series 921. http://whqlibdoc.who.int/trs/WHO 
 
Woo S-B, Hellstein JW & Kalmar JR. Bisphosphonates and osteonecrosis of the jaws. 
Ann Intern Med. 2006; 144: 753–761 
 
Yamaguchi T, Sugimoto T, Yamauchi M et al. Plasma lipids and osteoporosis in 
postmenopausal women. Endocr J. 2002; 49(2): 211-217 
 
Zhao L, Liu Y, Liu P et al. Relationship of obesity with osteoporosis. J Clin Endocrinol 

















- 103 - 
 
APPENDIX A 
TABLES AND FIGURES 
 
Correlation between height and total hip BMD in postmenopausal women 
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Correlation between WHR and total hip BMD in postmenopausal women 
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Correlation between TCG and total hip BMD in postmenopausal women 
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Correlation between SBP and lumbar spine in postmenopausal women 
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Correlation between HDL and lumbar spine in postmenopausal women 
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Non Parametric correlations between cardio-metabolic variables and BMD in 
postmenopausal women 
  total_hip_BMD spineT_cat 
 
abnormal_insulin Correlation Coefficient -.030 -.074 
Sig. (2-tailed) .757 .453 
N 106 106 
abnormal_fasting_glucose Correlation Coefficient -.115 .148 
Sig. (2-tailed) .239 .130 
N 106 106 
abnormal_TFT Correlation Coefficient .035 .027 
Sig. (2-tailed) .723 .783 
N 106 106 
xanthoma Correlation Coefficient .000 -.047 
Sig. (2-tailed) .997 .631 
N 106 106 
xanthelasma Correlation Coefficient .017 .017 
Sig. (2-tailed) .862 .866 
N 106 106 
arcus_senalis Correlation Coefficient -.183 .042 
Sig. (2-tailed) .060 .671 
N 106 106 
acanthosis_nigricans Correlation Coefficient .026 -.052 
Sig. (2-tailed) .789 .597 















A retrospective audit of the cardio-metabolic profile and bone mineral density in postmenopausal 
women attending Inkosi Albert Luthuli Central hospital menopause clinic from 01 July 2009 to 31 
December 2010 
 
SITE: Inkosi Albert Luthuli Central Hospital 
 
CHARACTERISTICS 
Study number:  _______                                          
 
Age:   _____years     
            
Ethnicity:   
African                  1 Coloured                         
Indian                            2 Caucasian                       
Other                                       
 
GYNAECOLOGICAL HISTORY 
Years since menopause  : _____years 
                                                                            1                 2 
presence of menopausal symptoms   yes            no        
… if yes:                                                                                                                                                   1 / 0 
*Vasomotor symptoms (hot flushes and nightsweats)                                                                              
*urogenital complaints -vaginal dryness & itching, discomfort during coitus, prolapse)                                                                                                                                         
*both                                                                                                                                                                
                                                                        1               2 
previous gynaecology pathology:   yes          no        
if yes…                                          1/0                                   1/0 
Abnormal uterine bleeding                                 Infertility                                        
Postmenopausal bleeding                                  Ovarian cysts                                  
Polycystic ovarian syndrome                             Other 
 
MEDICAL HISTORY                                                               
                                                   1/0                                                                                                  1/0 
Hypertension                                                                  Previous non-traumatic fractures     
Ischaemic heart disease                                               Past Pre-eclampsia                               
Diabetes                                                                          Past Gestational Diabetes                    
Hypercholesterolaemia                                               Impaired bone mineral density           
FAMILY HISTORY                                                                                                                            
Hypercholesterolaemia             1 /0                             Hypertension                       1/0                     1/0 
Non-traumatic fractures                                             Diabetes                                                IHD          
DRUG THERAPY                                          1/0                                                                                          
 
Steroids                                                                         Alternatives to HRT (to relieve flushes)          
Hormone replacement therapy                                    Statins                                                                    
Calcium supplements                                                     Antihypertensives                                             
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Vitamin D supplements                                                 Oral Hypoglycaemic agents                              
Calcium and Vitamin D supplements                          Insulin                                                                  
Antiresorptive drugs eg. Biphosphonates                  None of above                                                   
 
DIET                                                                                  SOCIAL 
                                                                                          Exercise 
Meat                           1                                                  Nil                          1     Walking               2  
Vegetarian                 2                                                  Sedentary           3      Gym                    4 
 
Level of eduction                                                             Employment 
Primary school                1                                            Unemployed                         1                                   
High school                      2                                             Employed                              2   
Tertiary                             3                              
Nil                             4 
 
Smoking      yes           1   no             2                  Alcohol       yes                       1       no        2 
      
PHYSICAL EXAMINATION 
Height (cm)                                       _______cm        
Weight  (kg)                                      _______kg 
Body mass index                             ------------ kg/m2                
Abdominal  circumference (cm)    _______cm      
Hip circumference(cm)                   _______cm 
Waist-Hip ratio                                 _______ 
 
Blood pressure:              Systolic  _______mmHg 
                                          Diastolic _______mmHg 
 
 
Stigma of dyslipidaemia                                          1/0                                1/0                      1/0 
Yes                                    1       (specify) xanthoma           xanthelasma            arcus senalis     
No                                     2 
Not documented           3 
 
Insulin resistance                                                           1/0 
yes                           1        1 acanthosis nigricans      
no                                2 
Not documented      3 
HAEMATOLOGICAL INVESTIGATIONS 
 
Abnormal lipid profile   
yes                           1 
no                             2   
not done                3 
 
 
 total serum cholesterol      _________mmol/L  
 fasting triglycerides             _________mmol/L 
 HDL                                         _________mmol/L 
 LDL                                         _________mmol/L 
        
2 
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Abnormal fasting glucose +/- GTT  
yes                       1   value:_______mmol/L 
no                         2 
not done             3 
 
 
Abnormal insulin                                 
yes                       1  value: _____iu/ml 
No                        2 
Not done             3 
 
 
Abnormal Thyroid function test   
yes                    1 value:_TFT___     T4(tyroxine)_____ 
No                       2 
Not done           3 
 
Hormone levels   






DEXA g/cm2 T score 
Total Hip   
Neck of femur   




















Low density lipo-protein (LDL ) 
Optimal:  <2.6 mmol/L 
near-above optimal : 2.6 – 3.3 
borderline high: 3.4 – 4.1 
high: 4.1 – 4.9 
very high  4.9 
 
High density lipo-protein( HDL) 
Favourable <1 mmol/L 




Borderline high 2.83 – 5.65 
Hypertriglyceridaemia >5.65 
Pancreatitis risk >11.3 
 
Cholesterol 
Normal <5.18 mmol/L 
Borderline high 5.18 – 6.19 mmol/L 
High ≥ 6.22 mmol/L 
 
Fasting Glucose 
normal 3.8 – 5.3 mmol/L 
 
 
Fasting Insulin  
Normal 3 – 25 mIU/ml 
 
TFT 
T4 (thyroxine) : normal 11-22.7 pmol/L 
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FSH in menopause 
23 -116 mIU/ml 
 
E2 (oestradiol) in menopause 
0-136 mIU/ml      
 
BMI (body mass index) 
Underweight: 10-18.5 
Healthy  18.5- 25 
Overweight 25-30 
Obese 30 – 40 
Very obese 40 - 70  
 
BMD (Bone mineral density) 
Tscore +2.5  to  -1.0 : normal 
Tscore -1.0 to -2.49 : osteopaenic 
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APPENDIX D 
SCORE RISK CHART 
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APPENDIX E 
HOSPITAL APPROVAL  
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